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1. Summary 
Prion diseases are fatal neurodegenerative disorders that can affect humans as well as a 
broad range of mammals (Aguzzi and Calella, 2009). The disease causing agent is the prion, 
a misfolded form of the cellular prion protein PrPC (Aguzzi and Calella, 2009). Apart from the 
fact that PrPC is an essential neuronal scaffolding protein (Bueler et al., 1993; Weissmann et 
al., 1994), the molecular mechanism underlying neurodegeneration in prion diseases is 
poorly understood (Aguzzi and Calella, 2009). 
Research on the neurodegenerative mechanisms of prion disease is hampered by the 
difficulty in propagating prions in cell lines (Rubenstein et al., 1984; Race et al., 1987; Butler 
et al., 1988; Schatzl et al., 1997; Bosque and Prusiner, 2000; Milhavet et al., 2000). In fact, 
even if propagation occurs, neurotoxic effects similar to those in prion diseases are not 
observed (Vilette, 2008). 
The aim of my first project was to assess whether the presence of glial cells would make 
neurons vulnerable to prion mediated toxicity. This approach was based on the observation 
that non-cell autonomous interactions with glial cells are crucial for neuronal loss in many 
neurodegenerative diseases (Lobsiger and Cleveland, 2007; Ilieva et al., 2009). In particular, 
I was interested in the non-cell autonomous effect of astrocytes because the accumulation of 
PrPSc appears at early stages of the disease (Diedrich et al., 1991) and significant changes in 
astrocytes occur during disease progression (Eklund et al., 1967). In addition, prion 
replication in astrocytes is sufficient to indirectly induce neurodegeneration in vivo (Raeber et 
al., 1997; Jeffrey et al., 2004).  
Previous results from our lab suggested that POM1, an antibody that mimics prion mediated 
toxicity, triggers neurodegeneration in mouse primary cortical neurons overexpressing PrPC 
only in presence of astrocyte conditioned media (ACM). However, these data were not 
reproducible. A robust readout was established with the almarBlue Assay cell viability assay 
that is based on the reducing environment of a viable cell (Nociari et al., 1998; Rampersad, 
2012). It was observed that ACM is not toxic to primary cortical neurons overexpressing PrPC 
or alters expression pattern of a set of immediate early genes (IEG) associated with 
neurodegenerative disease and/or synaptic plasticity.  
ACM alone was not sufficient to trigger neuronal loss upon POM1 treatment. Therefore, 
astrocyte neuron co-cultures were used for further experiments. The alamarBlue assay is not 
suitable to detect neuron specific cell death (Nociari et al., 1998; Rampersad, 2012); 
therefore, live cell imaging of fluorescently labeled neurons that allows defining early sign of 
neurodegeneration based on changes in neuronal morphology and number of surviving cells 
were performed. In particular, mouse embryonic stem cell (ESC) derived moto-, inter- and 
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pan neurons were used, which express wild type PrPC in co-culture with astrocytes. In none 
of these different neuronal populations POM1 mediated neurodegeneration was observed.  
Translational changes upon POM1 treatment were examined in human induced pluripotent 
stem cell (iPSC) derived pan neuronal cultures in sandwich culture with astrocytes. The 
expression level of proteins affected in prion disease did not reveal any changes upon POM1 
treatment. 
Since PrPC expression in astrocytes was sufficient for prion induced neuronal loss (Raeber et 
al., 1997; Jeffrey et al., 2004), the potential of astrocytes to become reactive after POM1 
treatment was tested. The transcriptional level of the reactive astrocyte markers LCN2 
(lipocalin-2) and GFAP (glial fibrillary acidic protein) (Zamanian et al., 2012) did not change 
after the application of POM1 to astrocytes and astrocyte/microglial co-cultures. 
In summary under the conditions studied, astrocytes were not able to render neurons 
vulnerable to POM1 mediated toxicity in vitro. It is possible that astrocytes alone are not 
sufficient or other structural aspects are needed to induce POM1 mediated cell death. 
POM2 an antibody against the flexible tail of PrPC is able to counteract POM1 and prion 
mediated toxicity (Sonati et al., 2013; Herrmann et al., 2015). In particular, it has been shown 
that the PERK (protein kinase RNA-like endoplasmic reticulum kinase) signaling branch of 
the unfolded protein response (UPR) is activated in POM1 and prion mediated toxicity, 
whereas POM2 treatment reduces this effect (Herrmann et al., 2015). Activation of the UPR 
upon ER stress is common to many neurodegenerative diseases (Hetz and Mollereau, 
2014). Therefore, the aim of my second project was to examine the role of PrPC as a general 
cell death transducer. To assess cell viability, live cell imaging was performed followed by 
morphometric analysis and measurement of the cell number with significant outgrowth. There 
are indications that POM2 can delay ER stress induced in mouse primary granule neurons 
overexpressing PrPC. POM2 was not able to counteract ER stress in PrPC depleted neurons 
suggesting that this effect is PrPC dependent.  
iPSC derived human neurons expressing wild type PrPC were exposed to POM2 before ER 
stress induction to examine if POM2 induces translational changes in the UPR. Upon strong 
induction of ER stress PrPC levels increased. Similar results have been already shown in a 
cancer cell line and in primary human neurons (Dery et al., 2013; Misiewicz et al., 2013), 
which support our hypothesis that PrPC is crucial for UPR signaling induced via ER stress. 
However, application of POM2 did not affect PrPC expression, which might be due to the 
strong induction of ER stress. ER stress induced by dysregulation of calcium homeostasis 
indicates that POM2 delays the activation of BiP, ATF4 and CHOP, which are involved in the 
PERK signaling branching affected in prion disease (Herrmann et al., 2015). 
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As a next step, the therapeutic potential of POM2 in vivo should be elucidated. My 
preliminary data are consistent with previous results from the lab and suggest that the 
intravenous application of POM2, which causes hemolysis, is not suitable for antibody 
delivery. Since it is assumed that hemolysis is mediated via complement activation, Dr. Vijay 
Chandrasekar designed an adeno associated virus (AAV) overexpressing the scFv POM2 
antibody lacking the Fc fragment responsible for complement activation and the fluorescent 
marker tdTomato. It was shown that the virus can efficiently transduce cerebellar brain slices 
and secreted POM2. Before testing the protective potential of the virus in complex in vivo 
model systems of neurodegenerative diseases, the virus was used to counteract 
photoreceptor mediated apoptosis in the mouse retina. This represents a simpler model 
system with a faster read out. Light induced phototoxicity causes photoreceptor loss in PrPC 
wildtype and PrPC depleted Balb/c retinas. However neither the expression of PrPC nor the 
transduction of AAV8 scFv POM2 could attenuate phototoxicity. One explanation could be 
that transduction was ineffective because cells were not labeled with the fluorescent marker 
tdTomato after infection. In addition, light induced photoreceptor toxicity activates the 
caspase-1 pathway (Grimm et al., 2000); whereas recent results suggest that prion mediated 
toxicity is calpain dependent (Sonati et al., 2013; Herrmann et al., 2015). Based on the 
different molecular mechanism leading to cell loss, the role of PrP may change. 
In summary, POM2 delays ER stress induced neurodegeneration; however, further studies 
will be necessary to confirm these results. 
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2. Zusammenfassung 
Prionenerkrankungen sind zum Tode führende neurodegenerative Erkrankungen, die sowohl 
bei Menschen als auch einer Vielzahl von Säugetieren auftreten können (Aguzzi and Calella, 
2009). Das krankheitserregende Agens ist das Prion (PrPSc), eine fehlgefaltete Form des 
zellulären Prion-Proteins (PrPC) (Aguzzi and Calella, 2009). Abgesehen von der Tatsache, 
dass PrPC ein essentielles neuronales Gerüstprotein ist (Bueler et al., 1993; Weissmann et 
al., 1994), ist der krankheitsunterliegende molekulare Mechanismus in Prionenerkrankungen 
unzureichend verstanden (Aguzzi and Calella, 2009). 
Die Erforschung des neurodegenerativen Mechanismus in Prionenerkrankungen wird 
dadurch erschwert, dass sich Prionen in Zellkulturen nur eingeschränkt propagieren lassen 
(Rubenstein et al., 1984; Race et al., 1987; Butler et al., 1988; Schatzl et al., 1997; Bosque 
and Prusiner, 2000; Milhavet et al., 2000). Selbst wenn eine Propagation stattfindet, können 
keine eindeutigen neurotoxischen Effekte an den Zellen beobachtet werden, die einer 
Prionerkrankung in vivo ähneln (Vilette, 2008). 
Das Ziel meines ersten Projektes war die Bewertung, ob in Gegenwart von Gliazellen 
Neuronen für Prionen vermittelte Toxizität anfällig werden. Diese Herangehensweise basiert 
auf der Beobachtung, dass nicht zellautonome Interaktionen mit Gliazellen wesentlich zum 
neuronalen Zellverlust in vielen neurodegenerativen Erkrankungen beitragen (Lobsiger and 
Cleveland, 2007; Ilieva et al., 2009). Insbesondere war ich interessiert am nicht 
zellautonomen Effekt von Astrozyten, da die Akkumulation von PrPSc im frühen Stadium der 
Krankheit stattfindet (Diedrich et al., 1991) und signifikante Veränderungen der Astrozyten 
während des Krankheitsverlaufs auftreten (Eklund et al., 1967). Ausserdem ist eine 
Prionenreplikation in Astrozyten ausreichend, um eine indirekte Neurodegeneration in vivo 
auszulösen (Raeber et al., 1997; Jeffrey et al., 2004).  
Vorhergehende Ergebnisse von unserem Labor legen nahe, dass POM1, ein Antikörper der 
Prionentoxizität nachahmt, nur in Gegenwart von Astrozyten konditioniertem Medium (ACM) 
zur Neurodegeneration in primären kortikalen Neuronen von Mäusen, welche PrPC 
überexprimieren, führt. Jedoch waren diese Daten nicht reproduzierbar. Ein robuster 
Readout wurde etabliert mit dem almarBlue Zellviabilitätsassay, welches auf dem 
reduzierenden Umfeld einer lebenden Zelle basiert (Nociari et al., 1998; Rampersad, 2012). 
Es wurde beobachtet, dass ACM nicht toxisch auf primäre kortikale Neuronen wirkt, welche 
PrPC überexprimieren, oder das Expressionsmuster von einem Set von Immediate Early 
Genes (IEG), welche mit neurodegenerativen Erkrankungen und/oder synaptischer Plastizität 
assoziiert sind, verändert. 
ACM alleine war nicht ausreichend um einen neuronalen Zellverlust durch POM1 
Behandlung auszulösen. Daher wurden Co-Kulturen von Astrozyten und Neuronen für 
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weitere Experimente verwendet. Der almarBlue Assay ist nicht geeignet um 
neuronenspezifischen Zelltod zu detektieren (Nociari et al., 1998; Rampersad, 2012). Daher 
wurde Live Cell Imaging von Fluoreszenz markierten Neuronen durchgeführt, welches die 
Bestimmung von frühen neurodegenerativen Veränderung in Form von neuronaler 
Morphologie und Anzahl der überlebenden Zellen ermöglicht. Dafür wurden eine Derivation 
von embryonalen Stammzellen (ESCs) der Maus in Moto-, Inter- und pan neuronale Kulturen 
durchgeführt, welche Wildtyp PrPC exprimieren. Diese wurden in Ko-Kultur mit Astrozyten 
gesetzt. In keiner dieser unterschiedlichen Populationen konnte eine POM1 vermittelte 
Neurodegeneration beobachtet werden.  
Humanen induzierte pluripotenten Stammzellen (iPSC) derivierte pan neuronalen Kulturen in 
Sandwich Kultur mit Astrozyten wurden verwendet, um translationale Veränderungen 
ausgelöst durch POM1 Behandlung zu untersuchen. Das Expressionslevel von Proteinen, 
die in Prionenerkrankungen betroffen sind, war nicht verändert.  
Da PrPC Expression in Astrozyten ausreichend ist, um neuronalen Verlust zu verursachen 
(Raeber et al., 1997; Jeffrey et al., 2004), wurde das Potential von Astrozyten nach POM1 
Behandlung reaktiv zu werden untersucht. Die transkriptionellen Level von den 
Astrozytenmarkern LCN2 (lipocalin-2) und GFAP (glial fibrillary acidic protein) (Zamanian et 
al., 2012) waren nicht verändert nach der Applikation von POM1 zu Astrozyten und 
Astrozyten/Mikrogila Ko-Kulturen.  
Zusammenfassend fanden sich keine Hinweise, dass unter den betrachteten Konditionen 
Astrozyten einen additiven POM1 vermittelten neurotoxischen Effekt auslösen. Es ist 
möglich, dass Astrozyten allein nicht ausreichen oder strukturelle Aspekte notwendig sind um 
POM1 vermittelten Zelltod in vitro zu induzieren. 
POM2, ein Antikörper gegen den flexiblen Schwanz von PrPC, ist fähig POM1 und Prion 
vermittelter Toxizität entgegenzuwirken (Sonati et al., 2013; Herrmann et al., 2015). Im 
Speziellen wurde gezeigt, dass der PERK (protein kinase RNA-like endoplasmic reticulum 
kinase) Signalzweig des Unfolded Protein Response (UPR) in POM1 und Prionen 
vermittelter Toxizität aktiviert ist, wohingegen POM2 diesem Effekt entgegenwirkt (Herrmann 
et al., 2015). Aktivierung des UPR durch ER Stress tritt in vielen neurodegenerativen 
Erkrankungen auf (Hetz and Mollereau, 2014). Daher war das Ziel meines zweiten Projektes 
die Rolle von PrPC als generellen Zelltodvermittler zu untersuchen. Um die Zellviabilität zu 
beurteilen, wurde Live Cell Imaging gefolgt von morphometrischer Analyse und Messung der 
Zellzahl mit signifikantem Auswuchs durchgeführt. Es gibt Hinweise, dass POM2 ER Stress 
in primären PrPC überexprimierenden Granularzellen der Maus, verzögern kann. POM2 war 
nicht fähig, ER Stress in PrPC knock out Neuronen entgegenzuwirken. Dies deutet darauf 
hin, dass dieser Effekt PrPC abhängig ist. 
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iPSC derivatisierte humane Neuronen, welche Wildtyp PrPC exprimieren, wurden vor der 
Induktion von ER Stress mit POM2 behandelt, um zu untersuchen, ob POM2 translationale 
Veränderungen im UPR auslöst. Die PrPC Expression war nach starker Induktion von ER 
Stress erhöht. Ähnliche Ergebnisse wurden bereits in einer Krebszelllinie und in primären 
human Neuronen gezeigt (Dery et al., 2013; Misiewicz et al., 2013). Dies unterstützt unsere 
Hypothese, dass PrPC essentiell für die ER Stress induzierte UPR Signalisierung ist. 
Allerdings konnte die Applikation von POM2 die PrPC Expression nicht beeinflussen, was 
möglicherweise an der starken Induktion von ER Stress liegt. ER Stress, induziert durch 
Fehlregulierung der Calcium Homöostase, deutet an, dass POM2 die Aktivierung von BiP, 
ATF4 und CHOP verzögert, welche in dem PERK Signalzweig involviert sind, welcher in 
Prionenerkrankungen betroffen ist (Herrmann et al., 2015). 
Als nächster Schritt sollte das therapeutische Potential von POM2 in vivo bewertet werden. 
Meine vorläufigen Daten stimmten mit vorherigen Ergebnissen aus dem Labor überein und 
deuten an das intravenöse Applikation von POM2 Hämolyse verursacht und deshalb nicht für 
die Antikörperzufuhr in vivo geeignet ist. Da angenommen wird, dass Hämolyse durch 
Komplementaktivierung verursacht wird, hat Dr. Vijay Chandrasekar einen Adeno 
Assoziierten Virus (AAV) generiert, der scFv POM2, ein Antikörper ohne Fc Fragment, 
welches für Komplementaktivierung verantwortlich ist und den fluoreszierenden Marker 
tdTomato überexprimiert. Es wurde gezeigt, dass der Virus effizient zerebrale Gehirnschnitte 
transduzieren kann und POM2 sekretiert. Bevor das protektive Potential des Virus in 
komplexen in vivo Modelsytemen von neurodegenerativen Erkrankungen getestet wird, 
wurde der Virus verwendet, um Photorezeptor vermittelte Apoptose in der Mausretina 
entgegenzuwirken. Dies stellt ein einfacheres Modelsystem mit einem schnelleren 
Ausleseverfahren dar. Licht induzierte Phototoxizität führte zu Photorezeptoren-Verlust in der 
Retina von PrPC Wildtyp und PrPC knockout Balb/c Mäusen. Jedoch konnte weder die 
Expression von PrPC noch die Infektion von AAV8 scFv POM2 die ausgelöste Toxizität 
abschwächen. Eine Erklärung hierfür könnte eine ineffektive Transduktion sein, da der 
fluoreszierende Marker tdTomato nach der Infektion nicht nachgewiesen wurde. Ausserdem 
ist bei Licht induzierter Photorezeptor Toxizität der Caspase-1 Signalweg aktiviert (Grimm et 
al., 2000), wohingegen kürzlich publizierte Ergebnisse darauf hindeuten, dass Prionen 
vermittelte Toxizität Calpain abhängig ist (Sonati et al., 2013; Herrmann et al., 2015). 
Basierend auf unterschiedlichen molekularen Mechanismen, die zum Zelltod führen, könnte 
die Funktion von PrP verändert sein. 
Zusammenfassend verzögert POM2 ER Stress induzierte Neurodegeneration. Jedoch sind 
weitere Studien nötig, um das Ergebnis zu bestätigen. 
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3. Abbreviation 
 
A Amyloid beta 
7ADD 7-Aminoactinomycin D 
ACM astrocyte conditioned media 
ALS Amyotrophe Lateral Sclerosis 
AM astrocyte media 
ATF4 activating transcription factor 4 
ATF6 activating transcription factor 6 
B2m Beta-2-Microglobulin 
BDNF brain-derived neurotrophic factor 
BSE bovine spongiform encephalopathy 
CC1 small charge cluster one domain 
CC2 charge cluster two domain  
CDP chronic demyelinating polyneuropathy 
CHOP C/EBP homologous protein 
CMV cytomegalovirus 
CNTF ciliary neurotrophic factor 
CREB cAMP response element binding protein 
CWD Chronic wasting disease 
DAPI 4′,6-diamidino-2-phenylindole 
Dpl Doppel 
EB embryoid body 
Egr1 Early growth response protein 1 
elF2α Eukaryotic translation initiation factor 2α 
ER Endoplasmic Reticulum 
ERK1/2 extracellular signal-regulated kinases 1 and 2 
FACS fluorescence-activated cell sorting 
FFI Fatal Familial insomnia 
FSC forward scatter 
FTgpi membrane-anchored version of the flexible tail of PrPC 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GCL ganglion cell layer 
GDNF glial cell-derived neurotrophic factor 
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GFAP glial fibrillary acidic protein 
GPI glycosyl phosphatidyl inositol 
GSS Gerstmann-Sträussler-Scheinker 
Gusb glucuronidase beta 
HB9 homeodomain transcription factor 9 
HC hydrophobic core 
Hmbs hydroxymethylbilane synthase 
HRP horse radish peroxidase 
IEG Immediate Early Genes 
INL inner nuclear layer 
IPL inner plexiform layer 
LCN2 lipocalin-2 
LIF leukemia inhibitory factor 
MAPK Mitogen-associated protein kinases 
mESC mouse embryonic stem cells 
mGluR5 metabotropic glutamate receptor 5 
NAD+ nicotinamide adenine dinucleotide (oxidized form) 
NADH nicotinamide adenine dinucleotide (reduced form) 
NT-3 neurotrophin-3 
ONL outer nuclear layer 
OPL outer plexiform layer 
OR octapetide region 
P/S penicillin/streptomycin1 
PBS phosphate buffered saline 
PERK Protein Kinase RNA-like Endoplasmic Reticulum Kinase 
PMD protein misfolding diseases 
POSCA prion organotypic slice culture assay 
Ppib peptidylprolyl isomerase B 
PrP prion protein 
PrPC cellular prion protein 
PrPSc prion scrapie 
qRT-PCR quantitate real time polymerase chain reaction 
RA retinoic acid 
RPE retina pigmented epithelium 
Abbreviation 
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rPrP recombinant prion protein 
SAG Smoothed agonist 
sCJD sporadic Creutzfeld-Jakob disease 
SD Standard deviation 
SNP single nucleotide polymorphism 
SP signal peptide 
SSC side scatter  
ST Staurosporine 
Tbp TATA-binding protein 
TBS tris buffered saline 
TH Thapsigargin 
TM Tunicamycin 
TMB 3,3’,5,5’-Tetramethylbenzidin 
TSE transmissible spongiform encephalopathy 
UPR Unfolded Protein Response 
VBA Visual Basic Application 
vCJD variant Creutzfeld-Jakob disease 
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4. General introduction to prion disease 
4.1. Prion disease 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), 
are caused by infectious self-replicating protein units (Kovacs and Budka, 2008). 
Prion diseases are fatal neurodegenerative disorders that affect humans and a broad 
range of mammals (Aguzzi and Calella, 2009). Prion diseases can be divided into 
genetic, acquired and sporadic forms, according to their etiology (Murdoch and 
Murdoch, 2015). The most striking feature of prion pathology is the spongiform 
degeneration of the brain (Budka, 2003; Kovacs and Budka, 2008). Other 
characteristics are neuroinflammation, synaptic impairment and the formation of 
plaques (Soto and Satani, 2011) (see Figure 1). Disease progression and symptoms 
depend on the trigger of the prion disease and the genotype involved (Aguzzi and 
Calella, 2009). Common clinical characteristics are dementia, cerebellar ataxia and 
motor dysfunction (Aguzzi and Calella, 2009). 
 
 
Figure 1: Characteristic pathological hallmarks of prion disease 
In prion disease PrPC is converted into its misfolded conformer PrPSc (Soto and Satani, 2011). The pathological 
features can be can be visualized by different staining techniques (Soto and Satani, 2011). PrPSc depositions are 
identified by immunohistochemistry with PrP specific antibodies (Soto and Satani, 2011). Silver staining is used to 
characterize the synaptic and dendrite loss (Soto and Satani, 2011). Spongiform degeneration is assessed by 
hematoxylin and eosin staining (Soto and Satani, 2011). Inflammation is characterized by immunohistochemistry 
with an anti-GFAP (glial fibrillary acidic protein) antibody that labels reactive astrocytes (Soto and Satani, 2011). 
Neuronal loss is visualized by caspase-3 antibody (red) and DAPI (4′,6-diamidino-2-phenylindole, blue) staining of 
nucleus (Soto and Satani, 2011). 
(Image: (Soto and Satani, 2011)) 
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The infectious agent, PrPSc, is a misfolded form of the cellular prion protein PrPC 
(Prusiner, 1998). Following conversion, PrPSc molecules can aggregate and recruit 
PrPC, supporting their own amplification (Aguzzi and Calella, 2009). 
It was previously thought that prion diseases are the only transmissible 
neurodegenerative diseases (Glatzel et al., 2005). Howeve,r there is now growing 
evidence that other protein misfolding diseases (PMDs) like Alzheimer’s disease, 
Parkinson and Huntington’s disease are also transmissible (Aguzzi and Rajendran, 
2009; Ashe and Aguzzi, 2013). Importantly, while many misfolded proteins involved 
in PMDs have been shown to be transmissible, they are not infectious which 
discriminates them from bona fide prions (Aguzzi and Lakkaraju, 2016). Therefore 
Prof. Aguzzi has introduced the term “prionoids” to describe these propagons (Aguzzi 
and Rajendran, 2009; Ashe and Aguzzi, 2013). 
As for many other neurodegenerative disorders, the chain of events that leads to 
neuronal loss is not resolved (Aguzzi and Falsig, 2012; Chiesa, 2015). However, it is 
known that PrPC expression is essential for prion-mediated neuronal loss (Bueler et 
al., 1993; Sailer et al., 1994). Moreover neuron-specific PrPC depletion in mice 
prohibits PrPSc induced neuro-toxicity (Race et al., 1995; Mallucci et al., 2003). 
 
4.1.1. Prion disease in animals 
In the 18th century prion disease was first recognized in sheep, and was termed 
scrapie (Jeffrey and Gonzalez, 2007). The name is attributed to the clinical sign 
observed in sheep, consisting of repetitive scratching (Lampert et al., 1972). In 
addition to sheep the disease was also found in goats and mouflons (Jeffrey and 
Gonzalez, 2007).  
In the 1960s chronic wasting disease (CWD) was discovered in North America 
(Williams and Young, 1980). This is the only known prion disease that occurs in 
wildlife, affecting elk, moose and deer (Haley and Hoover, 2015). The first cases of 
bovine spongiform encephalopathy (BSE) affecting cattle were described in the mid-
1980s (Wells et al., 1987). It is not clear how the disease first appeared in cattle. The 
most accepted theory supports transmission through feeding the cattle with prion 
infected meat and bone (Weissmann and Aguzzi, 1997). This disease variant also 
named “mad cow disease”, caused a lot of public attention because it was found to 
be transmissible to humans causing variant Creutzfeldt-Jakob disease (vCJD) 
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(Weissmann and Aguzzi, 1997). To reduce the spread of BSE many affected animals 
were killed and more stringent food controls were implemented. 30 years after the 
initial disease discovery, BSE is only rarely diagnosed (http://www.oie.int/en/animal-
health-in-the-world/bse-specific-data/number-of-reported-cases-worldwide-excluding-
the-united-kingdom/; http://www.oie.int/en/animal-health-in-the-world/bse-specific-
data/annual-incidence-rate/).  
 
4.1.2. Prion disease in humans 
Amongst prion diseases in human, sporadic CJD (sCJD) is the most common form 
(Aguzzi, Calella, 2009). In most cases of sCJD, the affected persons are 60-65 years 
old but the disease can occur in teenagers and more elderly people as well (Kovacs 
and Budka, 2009). After diagnosis of the disease, patients typically die within two 
years, or in most cases even after a few months due to the rapid progression of 
dementia associated with ataxia and mycoclonus (Kovacs and Budka, 2009).  
Genetic prion diseases are the next most frequent. Given that genetic prion diseases 
are caused by a mutation in the PRNP gene, it was suspected that somatic mutations 
in the PRNP locus occur also in sCJD (Prusiner, 1989). Furthermore it was 
suggested that the spontaneous conversion of PrPC to PrPSc (Aguzzi et al., 2008a; 
Colby and Prusiner, 2011) or that infections are responsible for acquiring of sCJD 
(Aguzzi and Calella, 2009). However, none of these hypotheses could have been 
proven and the etiology of sCJD remains enigmatic (Aguzzi et al., 2008a; Aguzzi and 
Calella, 2009). 
Prion diseases that are transmitted by direct contact with infectious material, 
including Kuru, iatrogenic and vCJD, are the least frequent form of prion diseases 
(Aguzzi and Calella, 2009). In the 1950s the first cases of Kuru in Papua New Guinea 
were reported (Gajdusek and Zigas, 1959, 1961). Kuru is characterized by cerebellar 
ataxia associated with tremor, choreiform and athetoid movements (Liberski et al., 
2012). It was presumed that the disease was caused by the ritual consumption of 
tissue from dead relatives affected with sporadic prion disease, a common practice of 
aborigines to show honor their death relatives (Alpers and Gajdusek, 1965; Collinge 
et al., 2006). 
vCJD is supposed to be caused by consumption of BSE affected cows (Aguzzi and 
Heikenwalder, 2006; Aguzzi and Calella, 2009). While direct experimental 
confirmation is missing, transmission of BSE to monkey and cows, epidemiological 
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and clinical and pathological studies as well as molecular biological experiments 
support this hypothesis (Aguzzi, 1996; Aguzzi and Weissmann, 1996; Bruce et al., 
1997; Hill et al., 1997). Similar to sCJD, the disease progression is rapid (Zeidler et 
al., 1997). 
Iatrogenic CJD is the most frequent form of prion diseases caused by contact with 
infectious material (Aguzzi and Calella, 2009). The transmission occurs accidently 
during medical procedures with patient material from affected donors or instruments 
that were before in contact with patients affected by prion disease. Documented 
examples include medical procedures including transplantation of dura mater, blood 
transfusions or positioning of stereotactic electrodes in the brain (Will, 2003). 
Between 5 and 15 % of human prion diseases are a result of dominant autosomal 
mutations in the PRNP gene (Aguzzi et al., 2008b; Aguzzi and Calella, 2009). The 
pathological features, onset of disease and the speed in disease progression are 
dependent on alterations in the PRNP gene (Aguzzi et al., 2008b). In 1936 the 
Gerstmann-Sträussler-Scheinker (GSS) disease was first described by Josef 
Gerstmann, Ernst Sträussler, and Ilya Mark Scheinker (Zeidman et al., 2014). The 
disease is caused by mutations at codons 102, 105, 117, 145, 198 and 217 in the 
PRNP open reading frame (Tateishi et al., 1988; Hsiao et al., 1989; Ghetti et al., 
1995; Aguzzi et al., 2008a). Compared to CJD, disease progression is rather slow (2-
10 years) with chronic progressive dementia and dementia occurring at the final 
stages of the disease (Aguzzi et al., 2008b). 1986 Fatal Familial insomnia (FFI) was 
discovered in an Italian family (Lugares, 1986). The disease is caused by a D178N 
point mutation in the prion gene and methionine-valine polymorphism at codon 129 
(Goldfarb et al., 1992). Characteristic features of the disease are sleep disturbance 
and diminished attention (Collins et al., 2001). 
Interestingly, carriers of the single nucleotide polymorphism (SNP) (M129V) at codon 
129 of PRNP are more susceptible to prion disease (Mitrova et al., 2005). In addition, 
this SNP influences the onset of disease (Poulter et al., 1992), disease progression 
(Mitrova and Belay, 2002) and clinical manifestation (MacDonald et al., 1996; Kovacs 
et al., 2000).  
 
4.2. Prion mediated toxicity 
Despite decades of prion research the mechanism underlying prion toxicity remains 
elusive. A neuroprotective function of PrPC has ben postulated by many independent 
studies (Roucou et al., 2004; Roucou and LeBlanc, 2005) suggesting that loss of 
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function causes neuronal cell death in prion disease (Hetz et al., 2003; Westergard et 
al., 2007). However, neither pre- nor postnatal ablation of PrPC has yielded any 
phenotypical prion pathology (Bueler et al., 1993; Mallucci et al., 2002) which leads 
to the assumption that loss of PrPC function in prion disease is rather unlikely (Aguzzi 
et al., 2008a). Alternatively, it is possible that the role of PrPC is only revealed under 
cellular stress and redundant under normal biological conditions (Harris and True, 
2006). 
Nevertheless experiments with PrPC knock out mice showed that PrPC is essential for 
prion mediated toxicity (Bueler et al., 1993; Weissmann et al., 1994). This result was 
confirmed by the fact that ablation of PrPC in early stages of prion infected mice could 
reverse spongiform changes, prohibit neuronal loss and progression to clinical stages 
of the disease (Mallucci et al., 2003). The engraftment of PrPC overexpressing tissue 
in the brain of PrPC knock out mice was followed by inoculation with PrPSc (Brandner 
et al., 1996b; Brandner et al., 1996a). In PrPC overexpressing tissue, replication of 
PrPSc as well as characteristic neuropathological changes of prion infection was 
reported (Brandner et al., 1996b; Brandner et al., 1996a). However, despite sufficient 
migration of PrPSc in PrPC depletion regions no histopathological changes were seen 
in PrPC deficient regions (Brandner et al., 1996b; Brandner et al., 1996a). Mice 
expressing PrPC mutants lacking the GPI (glycosylphosphatidylinositol)-anchor, 
which directs PrPC to the cell membrane, were able to replicate PrPSc but showed no 
signs of neurodegeneration (Chesebro et al., 2005). This lead to the conclusion that 
not only PrPC expression but also its cellular localization is crucial for of neuronal loss 
(Chesebro et al., 2005).  
So far the exact molecular mechanism underlying neurodegeneration in prion 
disease remains puzzling (Aguzzi et al., 2008b; Chiesa, 2015). One theory suggests 
that the prion protein itself is able to form a pore or interacts with cationic ion 
channels which leads to changes in the membrane potential causing cell death 
(Aguzzi and Falsig, 2012; Biasini et al., 2012). In particular it was observed that PrPC 
mutants lacking the central region or containing point mutations, associated with 
familiar prion disease, induced spontaneous currents in several cell lines (Solomon et 
al., 2010). This effect could be rescued via overexpression of full length WT PrPC 
(Solomon et al., 2010). Further evidence that ion channels might be involved in prion 
toxicity were provided by studies in PG14 mice (Tg) (PG14) mice (Senatore et al., 
2012) that contain octapeptide insertions related to a genetic prion disease in 
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humans (Chiesa et al., 1998). In this mouse line, the association of mutant PrPC with 
the voltage gated calcium channel α2δ-1 subunit leads to impaired 
neurotransmission, especially in cerebellar granule neurons (Senatore et al., 2012).  
In addition it is proposed that impairment in the UPR elicits the neuronal loss of prion 
disease (Moreno et al., 2012; Moreno et al., 2013). This will be explained in more 
detail in chapter 6.3.2.  
 
4.3. Structure of the cellular prion protein 
The prion protein is a membrane anchored glycoprotein (Paulick and Bertozzi, 2008) 
encoded by the PRNP gene, which has a highly conserved structure amongst 
different mammalian species (Basler et al., 1986).  
It includes an N-terminal flexible region, a globular domain containing three α-helices 
and a region with two antiparallel β-sheets that surround the globular domain (Riek et 
al., 1997; Zahn et al., 2000). The formation of a covalent disulfide linkage leads to the 
stabilization of the carboxy terminal region (Riek et al., 1996).  
The prion protein can be divided in two large units, a N-terminal flexible tail and a C-
terminal globular domain (Riek et al., 1997). The N-terminus consists of the signal 
peptide (SP), the small charge cluster one domain (CC1), the octapeptide region 
(OR), the charge cluster two domain (CC2) and the hydrophobic core (HC) (Aguzzi et 
al., 2008a; Aguzzi et al., 2008b). The SP is important for translation of PrPC in the 
endoplasmic reticulum (ER), where it undergoes several post-translation 
modifications including glycosylation, disulfide-bond formation and finally cleavage of 
the SP, before trafficking via the Golgi to the cell surface (Harris, 2003). Since the OR 
is able to bind copper (Brown et al., 1997) many studies have suggested a protective 
effect of PrPC against oxidative species (Steele et al., 2007). However, genetic 
ablation of PrPC in vivo causes no significant impairment of SOD activity (Hutter et 
al., 2003). The HC seems to be involved in the stability of PrPC because disease 
associated mutations in this region cause structural instability and misfolding of PrPC 
(van der Kamp and Daggett, 2010). In vitro studies of HC deletion mutants suggest 
an involvement of the HC in prion propagation (Holscher et al., 1998; Norstrom and 
Mastrianni, 2005).  
The α-helical structures within the GD undergo a drastic change to a beta-sheet rich 
structure during the conversion of PrPC into PrPSc (Caughey et al., 1991; Pan et al., 
1993; Safar et al., 1993). However, the physiological function of the GD is not well 
characterized (Ciric and Rezaei, 2015).  
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Figure 2: Primary structure PrPC 
The sequence of the PrPC primary structure contains the following consecutive domains from the N- to the C-
terminus: A secretory signal peptide (SP, orange), small charge cluster one (CC1, blue) the octapeptide repeat 
(OR, green), charge cluster two (CC2, blue), hydrophobic core (HC, dark grey), globular domain containing α1-, 
α2- and α3-helixes (yellow) (Dametto et al., 2015). In the above image, the following post-translational 
modifications are listed: glycosyl phosphatidyl inositol (GPI); facultative glycosylation sites (CHO) (Dametto et al., 
2015) . The region of the domains is defined by the number of respective amino acids (Dametto et al., 2015). 
[figure modified (Dametto et al., 2015)] 
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5. Investigation of the role of glial cells in prion toxicity 
5.1. Non-cell autonomous neurodegeneration 
Interestingly, most cell lines are resistant to prion infection (Bosque and Prusiner, 
2000), with only a few capable of to replicating prions, such as murine hypothalamic 
cell lines (Schatzl et al., 1997; Milhavet et al., 2000), the murine neuroblastoma cell 
line N2a (Race et al., 1987; Butler et al., 1988) and the rat pheochromocytoma cell 
line PC12 (Rubenstein et al., 1984). Nevertheless, none of these cell lines displayed 
neurotoxic effects as a result of prion infection (Vilette, 2008). Only hypothalamic 
GT1 cell lines have been shown to exhibit slight changes in cell viability (Schatzl et 
al., 1997; Milhavet et al., 2000). 
In primary neurons prion mediated toxicity was triggered via direct treatment with 
PrPSc infected brain homogenate (Cronier et al., 2004), prion-infected astrocytes 
replicating PrPSc (Cronier et al., 2012), purified PrPSc preparations (Muller et al., 
1993), specific peptides containing parts of the prion protein sequence (Forloni et al., 
1993) and by expression of PrPC deletion mutants (Watts et al., 2007). However, in 
all of these experiments, the absence of glia in neuronal cultures could not be 
confirmed, as all these models solely exploited glial-neuronal co-cultures (Forloni et 
al., 1993; Muller et al., 1993; Cronier et al., 2004; Cronier et al., 2012). Therefore, 
glial cells seem to be essential for prion-mediated neurotoxicity. 
In the past, the pathology of neurodegenerative diseases was mainly considered to 
occur in a cell autonomous manner, meaning that damage in neurons is sufficient to 
cause disease without the contribution of another cell type (Ilieva et al., 2009). This 
view has changed due to evidence that neuronal cell death is influenced by mutant 
protein expression or toxicity in non-neuronal cell types in the vicinity of affected 
neurons (Lobsiger and Cleveland, 2007). In particular glial cells seem to be involved 
in neurodegeneration, as is the case in amyotrophic lateral sclerosis (ALS), 
spinocerebellar ataxia, Huntington’s disease, and Parkinson’s disease (Lobsiger and 
Cleveland, 2007).  
It has been observed that astrocytes are involved in various cellular processes 
including the regulation of blood flow (Howarth, 2014; MacVicar and Newman, 2015), 
blood brain barrier integrity (Abbott et al., 2006), brain energy homeostasis (Belanger 
et al., 2011) and control of synapse formation and function (Clarke and Barres, 
2013). It has been shown that mis-regulation of some of these processes leads to 
neuropathological changes (astrocyte–neuron interactions in neurological disorders, 
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Ricci, 2009). For example, in Alzheimer’s disease it has been suggested that the 
blood brain barrier is impaired through a malfunction of astrocyte resident receptors 
responsible for shuttling of amyloid β (Aβ) from and into the brain [140, 141]. In 
addition it gas been proposed that Aβ changes calcium signaling of astrocytes and 
thereby may modulate synaptic plasticity [143].  
In prion disease, the accumulation of PrPSc takes place in astrocytes during early 
disease stages (Diedrich et al., 1991) with significant morphological abnormalities in 
astrocytes observed during disease progression (Eklund et al., 1967). The 
observation that expression of astrocyte PrPC is sufficient to induce susceptibility to 
prion disease (Raeber et al., 1997; Jeffrey et al., 2004) is supported by the concept 
that astrocytes could be the non-cell autonomous component in prion disease. 
However, these data is contradicted by the observation that depletion of PrPC in 
mouse models with early prion disease could reverse spongiform changes and 
prevent neuronal loss (Mallucci et al., 2003). 
 
5.2. In vivo and ex vivo models of prion disease 
Mice and hamsters represents the most frequent animal models for studying prion 
disease (Groschup and Buschmann, 2008; Watts and Prusiner, 2014). The 
advantage of hamsters is that they possess a very short incubation time before 
displaying a pathological phenotype (Kimberlin and Walker, 1977). However, for most 
in vivo prion studies mice are preferred over hamsters because they are easier to 
handle and this model offers superior genetic manipulation options (Watts and 
Prusiner, 2014). Disease progression in mouse models can be accelerated through 
overexpression of PrPC (Raeber et al., 1998). Nevertheless, the experiments remain 
time-consuming, expensive and the pharmacological manipulation of these rodent 
models are not very efficient (Doke and Dhawale, 2015). A great advance in the prion 
field was the invention of prion organotypic slice culture assays (POSCA) (Falsig et 
al., 2008), which closely simulate intracerebral infections with prions including 
characteristic features like prion propagation, inflammation, spongiform changes and 
neuronal loss (Falsig et al., 2012). Nevertheless, the slice culture system is complex 
which makes it challenging to discriminate between the effects from different cell 
types. Therefore it might be preferable to study cell-autonomous and non-cell 
autonomous mechanisms in a mono- or co-culture system. Cell culture systems have 
the advantage of being more suitable for experimental manipulations such as RNA 
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interference, calcium imaging and cell viability assays. Additionally, slice cultures are 
time consuming to prepare and not suitable for high-throughput screening. However, 
as mentioned under 5.1, prion toxicity could not be successfully reproduced in cell 
lines or pure primary neuronal cultures (Vilette, 2008). Prion mediated toxicity could 
only be found in primary neuron-glial co-cultures (Cronier et al., 2012; Cronier et al., 
2004; Forloni et al., 1993; Muller et al., 1993). Therefore, primary neurons in co-
culture with glial cells seem to be suitable for a prion in vitro model. 
 
5.3. Antibodies mimicking prion toxicity 
Recently it has been shown that antibodies targeting the globular domain of PrPC like 
POM1, elicited neuronal cell loss in cultured organotypic cerebellar slices, which 
appears to be mediated by pathways similar to prion infection (Sonati et al., 2013; 
Herrmann et al., 2015). In addition, the toxic effect of POM1 depends on expression 
levels of PrPC, as is also the case in prion infections (Sonati et al., 2013). This 
system represents a non-infectious model for prion disease with faster kinetics and 
allows us to focus on the toxic pathways involved in disease (Sonati et al., 2013; 
Herrmann et al., 2015). 
 
5.4. Scientific Aims 
One of the major aims of the thesis was to establish a cell culture model with the help 
of POM1 that reflects prion toxicity. This included the following steps: 
 It has already been shown that in primary neurons prion toxicity was mediated 
by the presence of glial cells (Cronier et al., 2012; Cronier et al., 2004; Forloni 
et al., 1993; Muller et al., 1993). 
 Therefore the potential of astrocytes and microglia to render primary neurons 
vulnerable to POM1 mediated toxicity was explored. 
 A suitable detection system was established for measuring POM1 mediated 
cell death in vitro.  
 POM1 mediated neuronal loss was assessed with the selected detection 
system. 
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5.5. Results 
5.5.1. Detection of POM1 mediated toxicity in a pure neuronal mono culture system 
5.5.1.1. Cell viability assays could not reveal any POM1 induced toxicity 
It has been proposed that disease progression in prion disease can be split into two 
phases: in the first phase prions replicate until they reach a plateau and in the 
second phase the clinical signs of the disease start to manifest (Sandberg et al., 
2011; Aguzzi and Falsig, 2012). To establish a cell culture model that replicates prion 
toxicity we used the anti-PrPC antibody POM1. POM1 is an antibody targeting the 
globular domain of PrPC (Polymenidou et al., 2008) and has been shown to mimic 
prion mediated toxicity in cerebellar organotypic slice cultures (Sonati et al., 2013; 
Herrmann et al., 2015). We selected this toxicity model over the use of prion infected 
brain homogenate for the following reasons:  
POM1 mediated toxicity and cell death is faster and only reflects the neurotoxic and 
not the inflammatory component of disease progression (Sonati et al., 2013; 
Herrmann et al., 2015). POM1 induced molecular changes can therefore be 
specifically attributed to toxicity.  
Furthermore, the antibody is considered a level 1 biosafety agent, which can be used 
for the design of easy-to-handle, infectivity-free model systems of prion toxicity 
(Sonati et al., 2013; Herrmann et al., 2015). 
The in vitro model system was initially analyzed by two former lab members; Dr. 
Tracy O’Connor and Sine Yaganoglu; POM1 was applied to primary cortical neuronal 
cultures supplemented with astrocyte media or astrocyte conditioned media collected 
from PrPC overexpressing (tga20) or PrPC knock out (ZH1) astrocytes. They 
observed no toxicity in pure cortical neuron cultures from tga20 mice overexpressing 
PrPC in astrocyte media, whereas variable results were obtained when neurons were 
grown in astrocyte-conditioned media. Neuronal loss was evaluated with the Lactate-
Dehydrogenase (LDH) Assay: cell death leads to the loss of the cell membrane 
integrity and LDH is released into the media (Korzeniewski and Callewaert, 1983; 
Decker and Lohmann-Matthes, 1988). LDH is quantified by its ability to reduce NAD+ 
to NADH (nicotinamide adenine dinucleotide), which then converts the tetrazolium 
salt Iodonitrotetrazolium to formazan in a colorimetric reaction (Korzeniewski and 
Callewaert, 1983; Decker and Lohmann-Matthes, 1988). The main limitation of the 
LDH assay is its dependence on the enzymatic activity of LDH, an enzyme prone to 
degradation, easily influenced by pH and compound/treatment condition changes in 
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the cell culture media (Galluzzi et al., 2009). Due to the unreliable readout of the LDH 
assay, the dependence of POM1 induced neurotoxicity in primary cortical neurons on 
astrocyte-secreted factors remains elusive. 
To further investigate this question, I1 tested additional cell viability/cytotoxicity 
assays to assess POM1 mediated toxicity in vitro. The following assays were 
selected: LIVE/DEAD assay, Cell Titer Glo and alamarBlue. 
Due to its robustness, easy and quick readout, the alamarBlue assay was chosen for 
further studies. The activate agent of the assay is resazurin, a nontoxic, cell 
permeable dye. In the reducing environment of a viable cell the compound is 
converted to resorufin, which exhibits a bright red fluorescence and represents a 
quantitative measure of cell viability (Nociari et al., 1998; Rampersad, 2012). To 
assess POM1 mediated toxicity in vitro, primary cortical neurons derived from tga20 
mice were plated in a 96-well plate. After 5 days the cells were treated with POM1 in 
astrocyte media (AM) or astrocyte conditioned media (ACM) obtained from tga20 
astrocytes. Recombinant prion protein (rPrP) was used to inhibit the effect of POM1. 
6h before the measurement, alamarBlue was added to neuronal cultures and 
endpoint readings were done at 24h and 48 h after addition of POM1. The applied 
concentration of 100 nM POM1 caused widespread neuronal death in cultured 
organotypic slices from tga20 pups (Sonati et al., 2013; Herrmann et al., 2015), yet 
the same concentration did not induce toxicity in cortical neurons cultured in AM or 
ACM. In contrast, the positive control Staurosporine (ST), a well-documented agent 
of apoptosis (Tamaoki et al., 1986; Kruman et al., 1998; Belmokhtar et al., 2001), led 
to decreased cell viability, confirming the validity of the assay.  
  
                                                 
1 Based on the suggestion of my thesis supervisor Prof. Dr. Adriano Aguzzi I elected to use the first-person 
narrative to make an unambiguous assignment to the experiments I have performed. For experiments where 
other persons where involved in planning, analysis and/or interpretation of the data I have chosen the “we” 
designation or particular mentioned the person who was involved in the experiment. 
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Figure 3: Cortical neurons in AM or ACM are not affected by POM1 treatment 
5 DIV (days in vivo) tga20 primary cortical neurons were treated with rPrP (300 nM), POM1 (100 nM) plus rPrP 
(600 nM) or ST (4 uM) in presence of AM or ACM. The cell viability of the neurons was assessed with the 
alamarBlue assay 24 h (A) or 48 h (B) after treatment. Each error bars indicate standard deviation (SD) of 3 
technical replicates. A one-way ANOVA with Dunnett’s post-test was used for this experiment and for all multiple 
comparisons (p < 0.005 = ***) 
 
5.5.2. Using molecular markers to evaluate POM1 mediated toxicity in cell culture 
5.5.2.1. Evaluation of transcriptional changes in POM1 treated primary cortical 
neurons  
Immediate Early Genes (IEG) are rapidly and transiently activated in response to a 
cellular stimulus (Kubik et al., 2007; Perez-Cadahia et al., 2011). In the brain they are 
involved in processes like neuronal plasticity and learning, suggesting that they might 
also be activated during the early stages of neurodegeneration (Qiao et al., 2007; 
Loebrich and Nedivi, 2009; Koldamova et al., 2014). In order to assess the role of 
IEG in POM1 toxicity, mRNA expression of specific IEG following POM1 treatment 
was quantified by qRT-PCR (quantitate real time polymerase chain reaction). 
I used 5 day old cortical neurons, treated with rPrP (600 nM), POM1 (200 nM) plus 
rPrP (600 nM), POM1 (200 nM) or ST (4 um) in ACM. After 1h incubation cells were 
lysed and collected for mRNA isolation. I initially identified a set of housekeeping 
genes with minimal variation in the experimental setup used here (Vandesompele et 
al., 2002). To proceed, I investigated the expression of housekeeping genes involved 
in different cellular pathways (see Table 1) across 12 samples (see Figure 4). 
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Table 1: Housekeeping genes for qRT-PCR 
Gene Function Reference
B2m Histocompatibility (Wang et al., 2010a) 
elF2α Protein translation (Kosir et al., 2010) 
GAPDH Glicolysis and gluconeogenesis (Seidler, 2013) 
Gusb Carbohydrate metabolism (Wang et al., 2010a) 
Hmbs Heme synthesis, porphyrin metabolism (Kosir et al., 2010) 
Ppib secretory pathway (Kosir et al., 2010) 
Utp6c Rn18 s biogenesis (Kosir et al., 2010) 
Tbp protein peptidyl-prolyl isomerization (Wang et al., 2010a) 
 
The qRT-PCR data was analyzed with a Visual Basic Application (VBA) for Microsoft 
Excel called GeNorm (Vandesompele et al., 2002). This application computes the 
gene-stability measure M for a selected gene by evaluation of the variation for all 
other control genes used (Vandesompele et al., 2002). The lowest M value, and the 
therefore lowest variability, was observed for elF2α, Htp6c and Ppib, which were 
therefore chosen for the normalization of my qRT-PCR data (see Figure 4). 
Interestingly, the M value for GAPDH was quite high compared to the selected 
genes. However, in many qRT-PCR protocols, this gene is used as reference (de 
Jonge et al., 2007; Kozera and Rapacz, 2013). This highlights the importance of 
selecting appropriate normalization controls to decrease the variability of results. 
 
 
Figure 4: GeNorm analysis 
qRT-PCR was done with isolated RNA from 1h with POM1 (200 nM), POM1 (200 nM) plus rPrP (600 nM) or ST 
(4 uM) treated and untreated cortical neurons in ACM (technical replicates RNA isolation n = 3; technical 
replicates qRT-PCR n=3). The M-Value was calculated with GeNorm, a Visual Basic Application (VBA) for 
Microsoft Excel. The genes with the lowest M-values are the most stable expressed ones. Therefore elF2α, Htp6c 
and Ppib were selected for normalization of the actual experiment.  
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I next decided on a set of IEGs to define early changes post POM1 treatment: Arc, 
CREB (cAMP response element-binding protein), c-Jun, Egr1 (Early growth response 
protein 1) and Homer1a. The transcription factor Egr1 is downregulated in prion 
disease (Booth et al., 2004; Sorensen et al., 2008) and in APP/PS1 Alzheimer’s 
disease animal models (Dickey et al., 2003; Dickey et al., 2004). The postsynaptic 
protein Arc is a downstream target of Egr1 (Koldamova et al., 2014) and involved in 
synaptic plasticity (Knapska and Kaczmarek, 2004; Kubik et al., 2007). In the 
Alzheimer mouse model, APPswe;PS1∆E9, the depletion of Arc prevents an activity 
dependent generation of Aβ suggesting an involvement or Arc in Alzheimer’s disease 
pathology (Wu et al., 2011). The transcription factor c-Jun is upregulated in primary 
cortical neurons in response to prion infection and treatment with the toxic human 
PrPC peptide PrP106-126 (Carimalo et al., 2005), and increases in cerebellar brain 
slices upon POM1 treatment (Herrmann et al., 2015). The (CaMK4β)/CREB signaling 
is misregulated in prion infected mice (Sorensen et al., 2008; Shott et al., 2014). The 
scaffold protein Homer1a is induced upon synaptic activity (Brakeman et al., 1997; 
Kato et al., 1998) and downregulated in an Alzheimer’s disease animal model 
(Dickey et al., 2003). Homer1a has also been reported to bind to metabotropic 
glutamate receptors (Brakeman et al., 1997), which have been shown to be bound by 
PrPC (Um et al., 2012; Um and Strittmatter, 2013). These reports suggest that Arc, 
CREB, c-Jun, Egr1 and Homer1a might also be affected during prion-induced 
toxicity, assessed by POM1 treatment. 
Cortical neurons in ACM were cultured and treated with POM1 (200nM) for 1h, 
neurons were collected and RNA was extracted as mentioned above. Expression of 
the previously mentioned IEGs after 1h treatment with POM1 was evaluated with 
qRT-PCR, yet none of the investigated genes significantly changed upon POM1 
treatment (see Figure 5). 
This observation could be due to several reasons. The selected genes are not 
affected after POM1 treatment or transcriptional changes occur in another time 
frame. As mentioned above astrocyte-secreted factors might be required for POM1 
mediated toxicity, and therefore also be required for the activation of IEG. We 
therefore decided to use an astrocyte-neuron co-culture for future experiments. 
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Figure 5: Expression of IEG after treatment of cortical neurons in ACM with POM1 
5 DIV cortical neurons were treated with POM1 (200 nM), POM1 (200 nM) plus rPrP (600 nM) or ST (4 uM). After 
1h incubation time the cells were lysed and collected for RNA isolation. After purification and reverse transcription 
of the mRNA, qRT-PCR was performed. The Relative Quantities (RQ) are based on the normalized to the house 
keeping genes pelF2α, Htp6c and Ppib. Each error bar indicates SD of 3 separate wells of cortical neurons 
analyzed (3 technical replicates for qRT-PCR were used = one dot). A one-way ANOVA with Dunnett’s post-test 
was used for this experiment and for all multiple comparisons. 
 
5.5.3. Detection of POM1 mediated toxicity in neuron astrocyte co-culture system 
5.5.3.1. Live cell imaging of POM1 treated neuron astrocyte co- culture systems 
The alamarBlue Assay is a useful tool to evaluate cell viability in a pure cell culture 
system but it cannot discriminate between cell viability of different cell types. In 
addition, only an endpoint measurement is possible, which makes it difficult to 
acquire information regarding behavior of the cell during treatment. Therefore, we 
decided to use live cell imaging as a read out for the POM1 treatment of astrocyte-
neuron co-cultures. 
To discriminate neurons from astrocytes fluorescently labeled neurons were used. 
Primary neurons from tga20 mice, overexpression PrPC, are not fluorescently tagged. 
As an alternative we derived neurons from mouse embryonic stem cells (mESCs) 
expressing a neuron-specific fluorescent marker. This assay has two significant 
advantages: (1) experiments can be better coordinated, since it is not necessary to 
rely on the mice estrous cycle of the animals, (2) derivation of neurons form mESCs 
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follows a strict protocol thereby reducing the likelihood for experimental 
inconsistencies.  
In particular, we decided to use two different mESC lines: 
 NT mESC line (Di Giorgio et al., 2007) for derivation of moto- and interneurons 
 TK-23 mESC line (Tucker et al., 2001) for derivation of a pan-neuronal culture 
 
For derivation of mESCs into moto- and interneurons I utilized a modified protocol 
(Wichterle et al., 2002), provided by my supervisor Dr. Vijay Chandrasekar (see 
Figure 6). Specific derivation of mESCs into moto- and interneurons was based on the 
addition of the following factors: retinoic acid (RA) and Smoothed agonist (SAG) (Di 
Giorgio et al., 2007). Further enrichment of a moto- and interneuron specific 
population was achieved via expression of GFP under the control of a moto- and 
interneuron specific promotor, the homeodomain transcription factor 9 (HB9) (Tanabe 
et al., 1998; Arber et al., 1999; Wilson et al., 2005). This leads to a bright expression 
of GFP in moto- and interneurons, which enables gating and enrichment of these cell 
populations by FACS (fluorescence-activated cell sorting) (see Figure 7). Selected 
cells were then directly sorted in with primary astrocyte-coated plates.  
 
 
Figure 6: Protocol for derivation of moto- and interneurons for mESC  
mESC were expanded on MEFs. On day 1 the cells were put into suspension culture were they aggregate and 
form structures named embryoid bodies (EBs). On day 3 and 5 neuronal differentiation was induced via RA and 
SAG. On day 7 the EBs were supported with the trophic factor GDNF (Glial cell-derived neurotrophic factor). The 
specific expression of GFP under a moto- and interneuron specific promotor enables the enrichment of the cells 
via FACS on day 8. After neuronal maturation for 1 day the experiment was started.  
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Motoneurons are not the main type of neurons affected in prion disease (Kovacs and 
Budka, 2009). Therefore, the generation of a pan-neuronal culture was needed to 
cover several types of neurons that could be affected in prion disease. For this 
purpose, the mESCs (TK23) were obtained from Austin Smith's group, United 
Kingdom (Tucker et al., 2001). For the derivation of a pan-neuronal linage, a 
suspension culture was used similar to that employed for moto- and interneuron 
generation. However, the induction of the neuronal linage was different. For the 
derivation of pan-neurons RA and Forskolin were added on days 5 and 7. On days 9, 
11 and 13 the cells were supported with GDNF. The TK23 mESCs express EGFP 
under the neuron-specific promotor Tau (Binder et al., 1985; Tucker et al., 2001). 
This allowed the neuronal selection via FACS on day 14. Directed differentiation 
towards a neuronal lineage was based on a standardized protocol provided by Vijay 
Chandrasekar (Ying et al., 2003). 
 
 
Figure 7: FACS example gating of NT mESC derived moto- and interneurons  
The gate P1 was used to select viable cells. The forward scatter (FSC) roughly defines size and shape and the 
side scatter (SSC) reflects the complexity and granularity of the cells. The P1 gate was used to exclude apoptotic 
(low FSC and high SSC) as well as dead cells (low FSC and low SSC). The plot GFP FITC-A vs. 7ADD PerCP-A 
was used to select the viable cells (low 7ADD PerCP-A signal) with am intermediated GFP signal (interneurons 
progenitors, gate GFP int) and a high GFP signal (motoneurons progenitors, gate GFP high). The histogram of 
the gate P2 reflects the counts of the GFP positive cells while the histogram of the gate GFP int and GFP high 
reflects the events of the inter- and motoneurons progenitors. 
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Figure 8: FACS example gating of TK23 mESC derived pan-neurons  
The viable cells were selected with gate P1. The forward scatter (FSC) roughly defines size and shape and the 
side scatter (SSC) reflects the complexity and granularity of the cells. The P1 gate was used to exclude apoptotic 
(low FSC and high SSC) as well as dead cells (low FSC and low SSC). The plot GFP FITC-A vs. 7ADD PerCP-
Cy5-5-A was used to select the viable cells (low 7ADD PerCP-A signal) with a high GFP signal (gate P3) and 
reflects the population of viable pan-neuronal progenitors. The histogram of the gate P2 reflects the counts of the 
GFP positive cells while the histogram of the gate P3 reflects the events of pan-neuronal progenitors. 
 
Neuronal morphology is a general parameter indicating health status (M et al., 2015). 
For characterization of neuronal morphology, images were processed using the 
MetaMorph Neurite Outgrowth software package (Molecular Devices), which enables 
calculation of morphological changes based on multiple parameters, namely neurite 
outgrowth, number of processes and number of branches (see Figure 9). 
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A) 
Imaging with Plate 
Runner 
 
(Bordet et al., 2007) 
 
 
 B) Image of motoneurons 
 
 
 C) 
Masking of neurons with 
MetaMorph 
 
 
Figure 9: Image processing with MetaMorph 
A) and B) Live cell images were acquired with the Plate Runner, a fluorescence imaging plate reader (Trophos). 
C) The image processing was performed using the MetaMorph neurite outgrowth program (Molecular Devices) to 
quantify total neuronal number and their morphological changes. The software masks neurons (see image C) 
cyan) and calculates the number of cells displaying significant outgrowth, the mean neurite length/cell, the mean 
branches/cell and the mean processes/cell. These parameters are then used to define morphological changes 
after treatment. 
 
5.5.3.2. Treatment of mouse moto- and interneuron astrocyte co-culture with POM1 
Motoneurons from NT mESCs were generated as described in 5.5.3.1 and plated 
with primary tga20 or Zurich 1 (PrP-/-) astrocytes. One day after plating, a baseline 
reading was performed and the astrocyte neuron co-cultures were treated with POM1 
(200 nM) or POM1 (200 nM) + rPrP (600 nM) in motoneuron media supplemented 
with GDNF and B27 minus antioxidants started. POM1 toxicity could be prevented by 
antioxidants (Sonati et al., 2013; Herrmann et al., 2015). Therefore, it was not used. 
Every other day the complete medium was exchanged and fresh POM1 was added. 
Neuron viability was evaluated with live cell imaging and morphological analysis of 
neurons was performed as stated in 5.5.3.1. 
Motoneurons plated with PrPC knock out or overexpressing astrocytes showed no 
significant changes in cells with significant neurite outgrowth (see Figure 10 A and 
C). At day 4 and 5 a decrease in the neurite outgrowth could be detected following 
POM1 plus rPrP treatment. This was somewhat surprising because rPrP was used to 
block the effect of POM1. 
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A) B) 
C)  D) 
Figure 10: POM1 treatment does not induce toxicity in motoneurons astrocyte co-cultures 
On day 1 NT mESC derived motoneurons, expressing wt PrPC, were plated in co-culture with tga20 astrocytes, 
overexpressing PrPC or ZH1 astrocytes, deficient of PrPC. From day 2 onwards cells were treated with POM1  
(200 nM) or POM1 (200 nM) + rPrP (600 nM). To assess cell viability the number of cells with significant 
outgrowth and changes in neuronal outgrowth were assessed. Neither in motoneurons in co-culture with PrPC 
expressing (A, B) nor PrPC depleted astrocytes (C, D) a significant neuronal loss or morphological changes could 
be detected following POM1 treatment. Each error bar indicates the SD of 5 (C, D) or 10 (A, B) technical 
replicates. A two-way ANOVA with a Bonferroni post hoc test was used for evaluation of this experiment whereby 
all samples were compared to untreated cells. Due to a reading error data points for POM1+rPrP at day 3 (C, D) 
are omitted. (p < 0.001 = ***, p < 0.1 = *) 
 
5.5.3.3. Treatment of mouse pan-neuron astrocyte co-culture with POM1 
While it was reported that motoneurons could be affected in prion disease patients 
(Worrall et al., 2000), conflicting studies suggests that this population of neurons are 
not especially affected in prion disease (Budka, 2003). This could be the reason for 
the lack of any toxicity after POM1 treatment of motoneurons. Therefore, we decided 
to repeat the experiment in a pan-neuronal culture derived from TK23 mESCs. 
Derivation of neurons was performed as is described in 5.5.3.1. After FACS sorting 
neurons were plated in co-culture with tga20 astrocytes. The absence of toxicity in 
the motoneuron co-cultures could indicate that the concentration of POM1 was 
insufficient to trigger neurodegeneration. Therefore, in this experiment several 
concentrations of POM1 were tested. In cerebellar slices from tga20 mice, neuronal 
loss could be detected after a 3 day treatment with 67 nM POM1 (Sonati et al., 2013; 
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Herrmann et al., 2015). Furthermore, it has been shown that the level of POM1 
toxicity is dose dependent (Sonati et al., 2013). Therefore, it was assumed that 
neuronal loss in the co-culture system could be observed if POM1 was used in a 
range from 50 nM to 250 nM. The advantage of TK23 derived pan-neurons is that 
they reflect a population of different types of neurons. However, compared to the NT 
mESC-derived motoneurons, TK23 mESC-derived pan-neurons show weak 
fluorescence. Thus only changes in cell number and not morphological differences in 
neurites could be evaluated with the MetaMorph software. None of the selected 
concentrations of POM1 induced notable toxicity within mESC-derived pan-neurons 
during the treatment period of 5 days (see Figure 11).  
 
 
Figure 11: Titration of POM1 in a TK23 pan-neuronal astrocyte co-culture 
TK23 mESC derived pan-neurons were co-cultured with primary tga20 astrocytes. One day after plating (day 2) 
pan-neurons were treated with different concentration of POM1. Treatment with IgG (200 nM) or ST (4 uM) was 
used as a negative and positive control respectively. Each error bar indicates average SD of 3-5 technical 
replicates (data points needs to be excluded because some images were overexposed and could not be properly 
analyzed by MetaMorph software). A two-way ANOVA with a Bonferroni post-hoc test was used for this 
experiment and all samples were compared to untreated cells. (p < 0.001 =****) 
 
5.5.4. Characterization of early molecular changes in human pan-neurons 
Based on the cell viability assays, POM1 did not reveal any toxicity. Therefore 
molecular changes upon POM1 treatment were explored. To evaluate changes of 
POM1 in a human context, we opted to use induced pluripotent stem cells (iPSC) 
derived pan-neuronal cultures. Derivation of pan-neuronal cultures was performed 
according to a protocol from Dr. Vijay Chandrasekar. In brief iPSCs were dissociated 
and placed in suspension culture to promote aggregation of EBs. For differentiation 
into a pan-neuronal linage retinoic acid and GDNF were added. After a differentiation 
period of 20 days, neurons were seeded on pre-coated plates or coverslips.  
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Figure 12: Protocol for derivation of iPSC derived neurons 
iPSCs were amplified and put in suspension culture on day 1 for derivation of human neurons. On day 11, 13, 15, 
17 and 19 the cells were driven towards a neuronal linage by addition of RA. From day 15 onwards the trophic 
factor GDNF was added. On day 21 the cells were digested and plated for the experiment. 
 
Murine primary astrocytes from wildtype C57BL/6J mice were split into pre-coated 
cell inserts. After 3 days mouse primary astrocytes were put in a sandwich culture 
with wildtype human neurons to commence treatment with POM1 (400 nM). Media 
supplemented with fresh POM1 was exchanged every other day and. Since 
antioxidants have been implicated to illicit a neuroprotective function against POM1-
mediated neuronal loss (Sonati et al., 2013; Herrmann et al., 2015), B-27 medium 
minus antioxidants was used during the whole antibody treatment. Since the cells are 
maintained in a sandwich culture, the neurons could be easily collected for western 
blot analysis after 7 days of treatment.  
For biochemical analysis the proteins P-elF2α, P-Erk1/2, P-Perk and Nur77 (NR4A1), 
were assessed because, they are known to be up regulated in POM1 and prion 
mediated toxicity (Herrmann et al., 2015). In addition, we checked the expression 
level of mGluR5, which has been implicated to interact with PrPC in Alzheimer’s 
Disease, thereby initiating neurodegeneration via the Fyn pathway (Um and 
Strittmatter, 2013). The levels of P-elF2α and P-Erk1/2 were slightly increased upon 
POM1 treatment but an even higher upregulation could be observed in human 
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neurons treated with POM1 and rPrP (see Figure 13 A and B). Western blot analysis 
of P-Perk showed only a weak signal at the predicted size of 170 kDa (see Figure 13 
C). This could be either due to a very low P-Perk expression level or perhaps to a 
technical problem while preforming the western blot. Levels of Nur77 show no 
obvious changes in the expression level (see Figure 14 A). However, upon POM1 
and POM1 plus rPrP treatment, the lower band around 70 kDa was shifted to a 
slightly increased molecular weight. POM1 and POM1 plus rPrP treated cells notably 
also displayed a down regulation in mGluR5 (see Figure 14 B). In general no 
significant changes were observed and pre-incubation of POM1 with rPrP seems to 
further pronounce the slight effect seen following POM1 treatment. However, this was 
merely a preliminary study with only one sample per condition. Accordingly, more 
replicates are needed to interpret the data.  
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Figure 13: POM1 co-culture human neurons – mouse astrocytes 
iPSC derived human neurons were co-cultured with primary mouse astrocytes and treated every other day with POM1 (400 nm) or POM1 (400 nm) plus rPrP (800nM) for 7 days. 
Human neurons were collected and P-elF2α (A), P-Erk1/2 (B) and P-PERK (C) protein levels were assed via western Blot. The western blot image quantification of the respective 
genes is shown below. 
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A) Nur77 
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Figure 14: POM1 co-culture human neurons – mouse astrocytes 
iPSC derived human neurons were co-cultured with primary mouse astrocytes and treated every other day with POM1 (400 nm) or POM1 (400 nm) plus rPrP (800nM) for 7 days. 
Human neurons were collected and Nurr77 (A) and mGluR5 (B) protein levels were assed via western Blot. The western blot image quantification of the respective genes is shown 
below. 
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5.5.5. Effect of POM1 treatment on astrocytes 
In vivo studies suggest that astrocyte specific PrPC expression is sufficient to induce 
prion mediated neurodegeneration (Raeber et al., 1997; Jeffrey et al., 2004). One 
hallmark of prion disease is astrogliosis (Budka, 2003; Liberski and Brown, 2004; 
Soto and Satani, 2011). LCN2 (lipocalin-2) and GFAP are genes highly upregulated 
at early stages of astrocytosis (Zamanian et al., 2012). To examine if astrocyte or 
astrocyte/microglia co-cultures become reactive after POM1 treatment, they were 
transfected with commercially available plasmids expressing the Firefly luciferase 
under the GFAP or LCN2 promoter and a control plasmid that expresses the Renilla 
luciferase under a ubiquitous promoter. One day after transfection, POM1 was added 
to the astrocytes and astrocyte/microglia co-cultures. Pre-incubation with POM2 or 
rPrP was used to inhibit the effect of POM1. The expression level of LCN2 and GFAP 
were determined after an incubation time of 48h and the consecutive addition of the 
substrates for the Firefly and Renilla luciferase. No significant induction upon POM1 
treatment of the astrogliosis markers could be observed in the cultures (see Figure 
15). This suggests that astrocytes do not become reactive after POM1 treatment. 
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A) B) 
C) D) 
E) F) 
Figure 15: POM1 treatment does not induce astrogliosis 
Primary astrocytes that are PrPC deficient (ZH1) (A-B) or overexpress (tga20) (C-D) or PrPC overexpressing 
astrocyte/microglia co-cultures (E, F) were transfected with reporter plasmids that express the Firefly luciferase 
under the GFAP or LCN2 promoter and a control plasmid that expresses the Renilla luciferase under a ubiquitous 
promoter. After 1 day the transfected cells were treated with POM1 (200 nM), POM2 (200 nM), POM1 (200 nM) 
plus rPrP (600 nM), POM1 (200 nM) plus POM2 (200 nM) and POM2 (200 nM) plus rPrP (600 nM). 48h later the 
LCN2 and GFAP levels were assessed by consecutively adding the substrate for the Firefly and Renilla 
luciferase. No significant changes could be observed in the expression level of LCN2 and GFAP. 
Each error bar indicates average SD of 4 technical replicates. A one way ANOVA with a Bonferroni post-hoc test 
was used for this experiment (compared groups: Untreated – POM1, Untreated – POM2, POM1 – POM1 + rPrP, 
POM2 – POM2+ rPrP). 
 
5.6. Discussion 
To date prion toxicity has not been observed in a pure neuronal cell culture (Forloni 
et al., 1993; Muller et al., 1993; Cronier et al., 2004; Cronier et al., 2012) suggesting 
that a non-cell autonomous mechanism is responsible for neurodegeneration in prion 
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disease. In my studies I was particularly interested in the involvement of astrocytes in 
PrPC mediated toxicity. 
POM1, an antibody binding to the globular domain of PrPC has successfully 
reproduced prion toxicity in organotypic brain slices (Sonati et al., 2013; Herrmann et 
al., 2015). Therefore, this antibody was applied to various primary, mESC derived 
and iPSC derived cell culture systems to explore which subset of cells are necessary 
for mediating prion toxicity. However, POM1 was unable to trigger neuronal loss 
under the conditions tested (see Figure 16). 
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Astrocytes does not become 
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Figure 16: Overview POM1 treatment in vitro 
A) – C) POM1 mediated toxicity was tested in mouse primary cortical neuronal cultures supplemented with or 
without ACM, mESC derived neurons in co-culture with mouse primary astrocyte, hiPSC derived neurons in co-
culture with mouse primary astrocytes. D) In addition, the potential of astrocyte to become reactive after POM1 
treatment was investigated. However, in none of these conditions changes upon POM1 treatment could be 
observed.  
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Table 2: Overview of in vitro POM1 toxicity experiments – POM1 toxicity experiments in different neuronal 
populations 
So far we did not observe POM1 mediated toxicity in the different neuronal population listed in table 1.  
 
Neuron type Species PrPC level 
neurons 
Longest 
treatment 
time 
Cell 
viability 
assed via 
 
Molecular 
changes  
POM1 
induced 
toxicity 
observed 
Pure Neuronal Culture
Cortical 
neurons 
Mouse Overexpression 3 days AlamarBlue, 
LDH Assay 
- No 
Astrocyte Conditioned Media 
Cortical 
neurons 
Mouse Overexpression 3 days AlamarBlue, 
LDH Assay 
- No 
Cortical 
neurons 
Mouse Overexpression 1h - Arc, 
CREB,  
c-Jun, 
EGR1, 
Homer1a 
No 
Neuron-Astrocyte Co-Culture 
Motoneurons Mouse WT 4 days Neuronal 
morphology 
- No 
Pan-Neurons Mouse WT 5 days Neuronal 
morphology 
- No 
Pan-Neurons Human WT 7 days - P-Erk1/2 
P-Perk, 
p-eIF2α, 
mGluR5, 
Nur77 
No 
 
Based on the experiments from Sine Yaganoglu and Dr. Tracy O’Connor it was 
suggested that astrocytes secrete one or more factors that mediate toxicity in cortical 
neurons. However, they could not reliably reproduce their results with the cytotoxicity 
assay (LDH-assay) they used. After the evaluation of several cell viability/cytotoxicity 
assays for this purpose, it was decided to use the alamarBlue reagent. However, I 
could not detect any toxic effect upon POM1 treatment of cortical neurons in ACM. A 
possible explanation is that the factor(s) in the ACM are too diluted to trigger toxicity 
or alternatively, that the assay is not sensitive enough to reveal minor changes in 
neuronal loss. Furthermore, it is possible that a direct neuron-astrocyte interaction is 
necessary for POM1 associated cell death. Therefore, it was decided to switch to 
neuron astrocyte co-cultures to assess POM1 mediated toxicity. However, most of 
the kits measuring cell viability/cytotoxicity are non-specific to neuronal loss and only 
detect the viability/cell death in the whole cell population. Thus, we switched to 
imaging of fluorescent labeled neurons and quantification of cell number and 
morphological changes for the detection of neurodegeneration. mESC derived moto- 
and pan-neurons expressing wild type PrPC did not reveal any changes in cell 
number or neuronal morphology that indicate neuronal loss after application of 
POM1.  
Investigation of the role of glial cells in prion toxicity 
41 
 
Another approach to detect POM1 mediated neurodegeneration is the evaluation of 
transcriptional changes in cortical neurons supplemented with AM or ACM. For this 
experiment, 1h after POM1 treatment samples were collected and qRT-PCR of the 
IEG Egr1, Arc, CREB, c-Jun and Homer1a, which are immediate early genes 
associated with neurodegenerative diseases and/or synaptic plasticity, was 
performed (Brakeman et al., 1997; Kato et al., 1998; Dickey et al., 2003). However, 
none of these genes changed in the expression level. This finding could be due to 
the fact that ACM alone is not sufficient to mediate POM1 dependent 
neurodegeneration. Furthermore, the expression pattern of the gene might be only 
changed during a particular time frame.  
For the assessment of translational changes upon application of POM1, it was 
decided to use human neurons co-cultured with mouse astrocytes, expressing wild 
type PrPC. Molecular biological studies of genes known to be changed after prion 
infection and POM1 treatment (P-Perk, P-elF2α, P-Erk1/2, Nur77) (Herrmann et al., 
2015) as well as mGluR5 which mediate neurodegeneration via PrPC interaction in 
Alzheimer’s disease (Um and Strittmatter, 2013) were not significantly changed. 
The absence of POM1 mediated neuronal loss in these experiments could be due to 
of several reasons. Motoneurons in particular are not very vulnerable to prion 
infection in vivo (Worrall et al., 2000; Budka, 2003). So the absence of toxicity would 
even confirm that POM1 resembles prion toxicity. However, in that case, at least in 
mouse and human pan-neuronal cultures with primary astrocytes, we would have 
expected that a proportion of neurons would have been affected by POM1 toxicity. 
The reason that we don’t observe a loss might be due to the surviving neurons that 
mask the effect of POM1.  
 
5.7. Outlook 
Within the incubation time and concentration of POM1 used, no prion mediated 
toxicity could be detected in mouse primary, mouse ESC derived or human iPSC 
derived neurons in co-culture with astrocytes. This is surprising because neuronal 
loss could be observed in primary astrocyte neuronal co-cultures treated with prion 
infected brain homogenate (Cronier et al., 2004; Cronier et al., 2012). However it 
could be that the neurodegeneration was induced via cytokines or other toxic 
components from the brain homogenate.  
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In the following section, possible approaches are listed to achieve POM1 mediated 
toxicity in vitro in post-mitotic neuronal cells. One opportunity to achieve POM1 
induced neurodegeneration is a mixed brain culture containing various cells resident 
in the brain. However, for that system it would be necessary to label the neurons or 
co-culture neurons in a mixed culture to specifically detect neuronal cell death. In 
case of neuronal cell death in the mixed culture through depletion of specific 
subtypes of cells (e.g. microglia, astrocytes) it could give an indication of which cell 
types are important for POM1 mediated toxicity. However, this approach is hampered 
by the fact that faster proliferating cells like fibroblasts overgrow these cultures and 
might deplete the effect of the cells important for POM1 mediated neurodegeneration. 
Morphology, cell signaling pattern, gene expression and polarity could be changed in 
2D cultures compared to in vivo system (Edmondson et al., 2014; D'Avanzo et al., 
2015). This might be one reason why POM1 mediated toxicity could not be observed 
in cell culture. An opportunity to reduce these changes is to culture the cells in 3D 
embedded in matrices generated with the help collagen, Matrigel and self-assembling 
peptides (SAP) like RADA16 (Liedmann et al., 2012). Especially the use of thin 3D 
cultures is well suitable for high throughput screenings (Seidel et al., 2012; Kim et al., 
2015b). 
 
5.8. Material and Methods 
All reagents are purchased at Thermo Fischer if nothing else is stated. 
5.8.1. Mice 
The housing of mice and animal experiments were performed according to Swiss 
Animal Protection Law and in compliance with the regulations of the veterinary office 
(canton Zurich). For our studies the following mice were included PrnpZH1/ZH1 mice 
(Bueler et al., 1992) and Prnpo/o;tga20+/+ (tga20) (Bueler et al., 1992; Fischer et al., 
1996). 
 
5.8.2. Primary cell culture 
5.8.2.1. Primary cortical neurons 
The primary cortical neurons were prepared according to a protocol from previous 
Post-Doc, Tracy O’Connor. Pregnant mice with E15.5 - E16.5 neurons were 
sacrificed and dissected down the midline to remove the uterus. The uterus was 
placed in Balanced Salt Solution (BSS; 10 mM HEPES, 1% Pen-strep in 1x Hank’s 
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balanced salt solution). After decapitating the embryos, the brain was isolated from 
skin and skull. Brains were transferred into fresh BSS to separate cortices from the 
rest of the brain. Meningee-free cortices were digested in Trypsin-solution (0.5 ml 
2.5 % Trypsin and 4.5 ml BSS) at 37°C for 15 min and washed three times with BSS. 
Cortices were triturated using a normal and then a fire-polished Pasteur pipette. 
Based on the experiment different amounts of cells were seeded into plates pre-
coated with 1 mg/mL poly-L-lysine. 
Cells were maintained in cortical neuron media (10% horse serum, 1% pen-strep, 1x 
B-27 supplement (Invitrogen) and 500 M glutamine in Neurobasal medium 
(Invitrogen). After four hours, neurons were switched to Neurobasal medium 
containing 1x B-27 supplement and 500 M glutamine. Medium was replaced every 
2-3 days. 
 
5.8.2.2. Primary astrocytes protocol 1 
Primary astrocytes were prepared according to a protocol of Tracy O’Connor. P1-P3 
mice were decapitated and brains were isolated in Balanced Salt Solution (BSS; 1x 
Hank’s Balanced Salt solution, 10mM HEPES, 1% P/S). After removing of the 
meninges, the cortices were digested with 0.5 ml 2.5 % Trypsin in 4.5 ml BSS for 15 
min at 37°C. For trituration astrocyte media (10% horse serum, 1% P/S q.s. Opti-
MEM) were added and after dissociation the cells were seeded into a 75cm2 flask 
(cortices from about 3 brains per flask). The next day the medium was changed and 
cells were maintained in astrocyte media. ACM used in all experiments in the study 
was collected from astrocytes prepared according to this protocol. 
 
5.8.2.3. Primary astrocytes protocol 2 
The primary astrocytes were prepared according to a modified primary astrocyte 
protocol 1 (denoted ‘Primary astrocytes protocol 2), which was provided by Dr. Vijay 
Chandrasekar. P1-P3 mice were decapitated and brains were isolated in Balanced 
Salt Solution (BSS; 1x Hank’s Balanced Salt solution, 10mM HEPES, 1% P/S). After 
removing of the meninges the cortices were minced and put for digesting with 0.25 % 
Trypsin for 15 min at 37°C. For trituration astrocyte media (10% horse serum, 1% 
P/S, 1.4% Glucose (45%) q.s. MEM) were added and after dissociation the cells were 
passed through a 70 um cell strainer. Cortices from about 3 brains were plated into a 
75cm2 flask pre-coated with Poly-D-Lysine (50 ug/ml, ≥ 30 min, 37°C, following three 
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consecutive washes with PBS). The next day the medium was changed and cells 
were maintained in astrocyte media.  
 
5.8.3. ACM Collection 
To obtain ACM astrocyte media, 10% horse serum, 1% P/S, 1.4% Glucose (45%) 
q.s. MEM was added to primary astrocyte cultures and after a certain time frame 
(normally 2 days) the media was collected and sterilely filtered to remove cell debris 
 
5.8.4. Collection of RNA for qRT-PCR  
Cortical neurons were grown in a 6-well format (600’000 cells/well). They were 
exposed to POM1, POM1 plus rPrP and rPrP in ACM at various time points. For RNA 
collection, samples were lysed in 350 ul/well RLT buffer from the RNeasy Mini-Kit 
(Qiagen) and frozen in liquid nitrogen. RNA purification was performed using the 
RNeasy Mini-Kit (Qiagen). Reverse transcription was done with the QuantiTect 
Reverse Transcription Kit (Qiagen). Used housekeeping gene primers are listed in 
Table 3 and primers to detect IEG are listed in Table 4. 
 
For qRT-PCR the following conditions were used: 
Table 3: Primer house keeping genes for qRT-PCR 
Primer name Gene Function Sequence (5’→3’) 
Amplicon 
length  
(bp) 
Reference 
Ppib fwd 
Ppib secretory pathway 
GGAGATGGCACAGGAGGAAA 
73 
(Kosir et al., 
2010) Ppib rev CCGTAGTGCTTCAGTTTGAAGTTCT 
Hmbs fwd 
Hmbs 
Heme synthesis, 
porphyrin 
metabolism 
TCCCTGAAGGATGTGCCTA 
73 
(Kosir et al., 
2010) Hmbs rev AAGGGTTTTCCCGTTTGC 
Hprt1 fwd Hprt1 Purine synthesis TCCTCCTCAGACCGCTTTT 90 (Kosir et al., 2010) Hprt1 rev CCTGGTTCATCATCGCTAATC 
Eif2a fwd 
Eif2a Protein translation 
CAACGTGGCAGCCTTACA 
74 
(Kosir et al., 
2010) Eif2a rev TTTCATGTCATAAAGTTGTAGGTTAGG 
Utp6c fwd Utp6c Rn18 s biogenesis 
TTTCGGTTGAGTTTTTCAGGA 75 (Kosir et al., 2010) Utp6c rev CCCTCAGGTTTACCATCTTGC 
B2m fwd B2m Histocompatibility GGTCTTTCTGGTGCTTGTCTCA 103 (Wang et al., 2010a) B2m rev GTTCGGCTTCCCATTCTCC 
Gusb fwd Gusb Carbohydrate metabolism 
CCGATTATCCAGAGCGAGTATG 197 (Wang et al., 2010a) Gusb rev CTCAGCGGTGACTGGTTCG 
Tbp fwd 
Tbp 
protein peptidyl-
prolyl 
isomerization 
CAAACCCAGAATTGTTCTCCTT 
131 
(Wang et al., 
2010a) Tbp rev ATGTGGTCTTCCTGAATCCCT 
Gapdh fwd 
Gapdh Glicolysis and gluconeogenesis 
TCCATGACAACTTTGGCATTG 
72 
Platform 
genomics – 
University of 
Geneva 
Gapdh rev CAGTCTTCTGGGTGGCAGTGA 
 
  
Investigation of the role of glial cells in prion toxicity 
45 
 
Table 4: primer IEG for qRT-PCR 
Primer name Gene Sequence (5’→3’) 
Amplicon  
length  
(bp) 
Reference 
Arc fwd Arc TGCAATACAGTGAGGGTACACT 107 fwd: Sine Yaganoglu rwd: (Santini et al., 2011) Arc rwd TCCCGCTTGCGCCAGAGGAACT 
CREB fwd CREB CTGCCTGAAAGCAACTACAGAAT 111 Sine Yaganoglu CREB rwd TCTCTTCATGATTCCTGGCGCT 
Egr1 fwd Egr1 CGAGTTATCCCAGCCAAACG  Sine Yaganoglu Egr1 rwd GAGGCAGAGGAAGACGATGA 
Homer1a fwd Homer
1a 
GAAGTCGCAGGAGAAGATG 134 fwd: (Mahan et al., 2012) rwd: Sine  Homer1a rwd AGTTCTGTGTCACATCGGGTGT 
c-Jun fwd c-Jun CACCAACTGCTTGGATCC  Sine Yaganoglu 
c-Jun rwd AGGAAAGTTGCTGGCCGGTA 
 
qRT‐PCR parameters: 
Hold stage: 50 °C, 2 min; 95°C, 10 min 
PCR stage (40 cycles): 95 °C, 15 sec; 60°C, 1 min 
Melt curve: 95 °C, 15 sec; 60°C, 1 min, 95 °C, 1 min 
 
5.8.5. Preparation of astrocytes for sorting mESCs 
At least one day before sorting mESCs, 96-well plates were pre-coated with Poly-D-
Lysine (50 ug/ml, ≥ 30 min, 37°C, following three consecutive washes). 10’000 
astrocytes were plated per well.  
 
5.8.6. Derivation of neurons from mESCs 
In vitro derivation of mESC was performed according to a modified protocol 
(Wichterle et al., 2002; Ying et al., 2003), provided by Vijay Chandrasekar. Irradiated 
mouse embryonic fibroblasts (MEFs; CF-1 MEF 4M IRR, GSC-6001G, ams 
biotechnology) were seeded on Petri dishes pre-coated with 0.1 % gelatin (ES-006-B, 
Millipore) and supplemented with MEF medium (10 % FBS, 1 % P/S, 1x Glutamax, 5 
ml MEM-nonessential amino acids (NEAA) q.s. DMEM). The mESCs were expanded 
on irradiated MEFs maintained in ESC-media (90 ml ES Cell FBS, 6 ml 2-
Mercapthoenthanol, 5 ml P/S, 6 ml NEAA, 5 ml Glutamax, Leukemia Inhibitor Factor 
(LIF) q.s. KNOCKOUT-DMEM). For generation of EBs the mouse embryonic stem 
cells were trypsinized and re-suspended in EB-media (50 ml KOSR, 5 ml P/S, 4 ml 2-
Mecrapthoenthanol, 3.75 ml Glutamax, q.s. DMEM/F12) on day 1. To promote 
cellular aggregation into EBs, cells were transferred into bacterial dishes and put into 
suspension cultures.  
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Derivation of moto- and interneurons 
Derivation of moto- and interneurons was based on a from Vijay Chandrasekar 
modified protocol (Wichterle et al., 2002). On day 3 and 5 the EB-medium was 
exchanged and retinoic acid (0.1 mM RA; 1:10 000) and smoothed agonist (0.25 uM 
SAG; 1:1000, VWR Internat. AG Life Sciences 566660) were added to drive neurons 
towards a moto-/interneuron linage. At day 7, EB-medium was exchanged and GDNF 
(0.1 ng/ml) was added. At day 8 the EBs were collected and allowed to settle in a 
Falcon tube. After careful removal of the media, Papain (Worthington) was added 
and cells were digested at 37°C for 5 min. Following gentle re-suspension, cells were 
filtered through a 70 um cell strainer and loaded on an Ovomucoid-Inhibitor gradient 
(Worthington). After centrifugation at 500 rcf for 5 min media was aspirated and cells 
were re-suspended in FACS media (2 % horse serum, 1 % P/S q.s. DMEM/F12). 
 
Derivation of pan-neurons 
The derivation of the pan-neurons is similar as for the moto- and interneurons. 
However the induction pattern is different. For the derivation into a pan-neuronal 
lineage RA and Forskolin were added on day 5 and 7 and on day 9, 11 and 13 the 
cells were supported with GDNF according to modified protocol from Vijay 
Chandrasekar (Ying et al., 2003). 
mESC derived neurons were maintained in neuron media (50 ml horse serum, 1x N2 
supplement, 1x B27 supplement, 1 % P/S, q.s. DMEM/F12). The trophic factors 
GDNF, BDNF (brain-derived neurotrophic factor), CNTF (ciliary neurotrophic factor) 
and NT-3 (Neurotrophin-3) were added to a final concentration of 0.1 ng/ml, if not 
stated otherwise. 
 
5.8.7. FACS-sorting 
The cells were sorted with a BD FACS Aria™ III sorter (BD Bioscience) using a 75 or 
100 um nozzle. The cells were directly sorted into 96 well plates containing astrocyte. 
One day after plating, medium was exchanged and, dependent on the experiment, 
trophic factors were added. 
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5.8.8. Derivation of iPSCs derived pan-neurons 
Derivation of mESC was performed according to a protocol form Dr. Vijay 
Chandrasekar. Irradiated mouse embryonic fibroblasts (MEFs; CF-1 MEF 4M IRR, 
GSC-6001G, ams biotechnology) were seeded on Petri dishes pre-coated with 0.1 % 
gelatin (ES-006-B, Millipore) and supplemented with MEF medium (10 % FBS, 1 % 
P/S, 1x Glutamax, 5 ml MEM-nonessential amino acids (NEAA) q.s. DMEM). The 
iPSCs were expanded on irradiated MEFs maintained in iPSC-media (390 ml 
KNOCKOUT-DMEM, 100 ml knockout serum, 1% Glutamax, 5 ml NEEA, 40 ug 
fibroblast growth factor recombinant human protein). On day 1 iPSCs were 
trypsinized and re-suspended in human EB-media (390 ml KNOCKOUT-DMEM, 100 
ml knockout serum, 1% Glutamax, 5 ml NEEA). Cells were transferred to low 
attachment flasks to promote cellular aggregation into EBs. On day 11, 13, 15, 17 
and 19 RA (10 nM) was added. From day 15 onwards, cells were additionally 
supported with GDNF (1 ng/ml). On day 21 EBs were collected and allowed to settle 
in a Falcon tube. After careful removal of the media, papain (Worthington) was added 
and cells were digested at 37°C for 1h. Following gentle re-suspension cells were 
filtered through a 70 um cell strainer and loaded on an Ovomucoid-Inhibitor gradient 
(Worthington). After centrifugation at 500 rcf for 5 min media was aspirated and cells 
were re-suspended in human pan-neuronal media (1x N2 supplement, 1x B27 
supplement, 4 ml D-glucose 45%solution, 4 ml ascorbic acid (50 mM), 500 ul GDNF 
(1 ug/ml), 500 ul BDNF (1 ug/ml), 500 ul CNTF (1 ug/ml), 500 ul NT-3 (1 ug/ml) q.s. 
DMEM/F12). Cells were plated on laminin/lysine pre-coated plates and maintained in 
human pan-neuronal media. 
 
5.8.9. Preparation of astrocytes for iPSCs derived neurons co-culture 
Primary astrocytes were washed once with PBS. After digestion with trypsin 700’000 
cells were plated in Poly-D-Lysine pre-coated inserts (Millipore). One day after plating 
astrocyte media was changed. Three days after seeding, astrocytes they were put in 
co-culture with 6 week old iPSC derived neurons in human neuron media with B-27 
minus antioxidants (1.5 ml per insert and 2 ml per well of a 6 well plate).  
 
5.8.10. Treatment of iPSCs derived neurons with POM1 
iPSCs derived neurons in co-culture with astrocytes were treated with 400 nM POM1. 
Complete media supplemented with fresh POM1 was changed every other day. 7 
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days after treatment cells were collected for western blot in RIPA-Buffer containing 
protease and phosphatase inhibitors.  
 
5.8.11. Morphological analysis  
Live cell images were processed with the neurite outgrowth program of the Meta 
Morph Software (Molecular Devices).  
 
5.8.12. Western blot 
The cells collected in lysis buffer were homogenized for 30s (frequency 30 Hz) and 
put for 1 min on ice. This step was repeated 3 times and followed by three 
consecutive freeze thaw cycles in liquid nitrogen. In order to remove the cell debris 
the samples were centrifuged at 15’000 g for 15 min at 4°C. For quantification of the 
protein concentration a BCA-Assay (Pierce) was done according to the 
manufacture’s protocol. 25 ug sample was diluted in loading dye and DTT (final 
concentration 100 mM) and heated for 5 min at 95°C. After a quick spin the samples 
were loaded on the gel (Novex, NuPAGE, Bis-Tirs gel) and SDS gel electrophoreses 
run. The samples were transferred to a polyvinylidene difluoride (PVDF) membrane 
with the iBlot dry blotting system (life technologies). Membranes were blocked with 
blocking buffer (5% Top Block diluted into PBS-Tween). After 1h blocking the 
membranes were incubated with the primary antibody (mGluR5 (Abcam, # ab53090), 
Nur77 (CST, # 3960S), P-elF2α (CST, # 9721S), P-Erk1/2 (CST, # 4370S), P-Perk 
(CST, # 3179S)) diluted in blocking buffer overnight at 4°C. After 3 washing steps 
with blocking buffer the membrane was incubated with the secondary antibody for  
1-2 h followed by 4 consecutive washing steps. The membrane was developed with 
Western HRP Substrate Luminata Crescendo (Millipore) for 4 min. The blots were 
imaged with the Stella (Raytest) and semi-quantitative analysis was done with the 
Quantity-One (Bio-Rad) software. 
 
5.8.13. Preparation of astrocytes or astrocyte/microglia cultures for Dual-Luciferase reporter 
assay 
Primary astrocytes were washed once with PBS and fresh media was added. 
Astrocyte cultures were placed on an orbital shaker for 3h to remove microglia or 
mixed astrocyte/microglia cultures were split directly into a 96 well plate (10’000 
cells/well). One day after plating, cells were transfected with the LCN2-Firefly 
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Luciferase (addgene, #25463) and Renilla Luciferase plasmid or with GFAP-Firefly 
Luciferase (addgene, #40589) and Renilla Luciferase plasmid. For transfection 
Lipfectamine 3000 was used. The DNA ratio LCN2 or GFAP to Renilla plasmid was 
9:1.  
 
5.8.14. AlamarBlue Assay 
Experiments were performed in a 96 well plate containing 90 ul of media. 6h before 
the defined time point 10 ul of alamarBlue was added. Following a 6h incubation, 
plate fluorescence was assessed with an EnVision Reader (Perkin Elmer) using 
560EX nm/590 EM nm filter settings or 531 EX nm/590 EM nm filter settings (plus 
mirror through which only EX < 555 nm pass and only Em > 555 nm pass through). 
 
5.8.15. Dual-Luciferase reporter assay 
The Dual-Luciferase reporter assay (Promega) was used for quantification of 
Luciferase activity. For lysis, astrocyte media was removed and 25 ul Passive Lysis 
Buffer (PLB) was added. After 15 min shaking (1000 rpm, 20 °C) Luciferase Assay 
Reagent (LAR) containing the Luciferase substrate was added and 120 ul/well of 
suspension mix was transferred to a fresh white plate suitable for measuring 
luminescence. Luciferase activity was measured with an EnVision Reader (Perkin 
Elmer). The Stop & Glo Reagent, which simultaneously quenches the Firefly 
Luciferase signal and initiates the Renilla Luciferase reaction, was added and the 
activity of Renilla Luciferases was measured with the EnVision Reader (Perkin 
Elmer) according to the manufacture’s protocol. 
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6. Potential function of PrPC as a cell death transducer 
6.1. Proposed physiological role of PrPC 
PrPC expression starts during early embryogenesis (Manson, 1992; Harris 1993). In 
adult mammalian species expression is found in many cell types with a particularly 
high enrichment in neurons (Kretzschmar et al., 1986; Moudjou et al., 2001). 
Evidence in favor of an important biological function of PrPC are, the high structural 
conservation of PrPC (Roucou et al., 2004), no naturally occurring Prnp-null alleles 
are observed throughout the mammalian kingdom (Aguzzi and Calella, 2009; 
Benestad et al., 2012). The use of PrPC knock-out mice has not shed much light on 
the role of this gene (Weissmann and Flechsig, 2003; Steele et al., 2007). In the 
Zurich II, Nagasaki and Rcm0 PrPC knock out mouse strains, cerebellar degeneration 
and ataxia has been observed that could be rescued by the re-introduction of PrPC 
(Weissmann and Flechsig, 2003). While this observation endorses the essential role 
of PrPC in maintaining a healthy neuronal status, the Zurich I and the Edinburgh 
knock out lines fail to demonstrate this striking phenotype (Weissmann and Flechsig, 
2003; Linden et al., 2008). In fact, it turns out that, this phenotype represents a 
genetic artifact introduced by the different strategies used to generate these mouse 
strains (Linden et al., 2008). In the Zurich I and the Edinburgh lines, ablation of the 
prion protein has been achieved by modifying the exon 3, which contains the ORF of 
Prnp (Weissmann and Aguzzi, 1999; Weissmann and Flechsig, 2003). A more 
aggressive approach has been used in the Zurich 2, Nagasaki and Rcm0 PrPC knock 
out mouse lines, where the flanking regions of the ORF were also disrupted 
(Weissmann and Aguzzi, 1999; Weissmann and Flechsig, 2003). Therefore, the 
acceptor splice site in the Prnp gene was lost, which in turn lead to Doppel (Dpl) 
overexpression, encoded by Prnd located 16 kDa downstream of Prnp (Moore et al., 
1999). Dpl is a GPI anchored membrane protein that shares about 25 % sequence 
similarity with PrPC (Moore et al., 1999). Interestingly Dpl and PrPC have common 
features in the globular domain while an equivalent to the octapeptide region of PrPC 
is missing in Dpl (Moore et al., 1999). In wild type mice Dpl is highly expressed in the 
testis, to some extent in peripheral organs and at very low levels in the brain 
(Silverman et al., 2000) (see Figure 17).  
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Figure 17: Involvement of the flexible tail of PrPC in neurotoxic signaling  
(A) Prnd is encoded downstream of Prnp separated by an intergenic region (Weissmann and Flechsig, 2003). (B) 
Through aggressive depletion of the Prnp coding region in exon 3 the splice acceptor site can be lost (Weissmann 
and Flechsig, 2003). This leads to exon skipping and transcription of chimeric mRNAs encoding Prnd regulated 
by the Prnp promotor (Weissmann and Flechsig, 2003), 
Figure modified from (Weissmann and Flechsig, 2003)  
 
Besides the phenotypes caused by genetic artifact, the most striking feature common 
for PrPC knock out mice is that they are resistant to prion infection (Weissmann and 
Flechsig, 2003; Steele et al., 2007) and lack a relevant pathological phenotype 
(Bueler et al., 1993; Prusiner et al., 1993; Sailer et al., 1994). Hypothetical 
mechanisms underlying this observations include compensation by another protein or 
that the function of PrPC is dependent on undefined selective pressures, which would 
make it challenging to reveal the role of PrPC (Roucou and LeBlanc, 2005; Steele et 
al., 2007). Nevertheless, intensive studies of histopathological changes have 
revealed that depletion of PrPC causes a chronic demyelinating polyneuropathy 
(CDP) (Nishida et al., 1999; Baumann et al., 2007; Bremer et al., 2010). More 
specifically, it has been reported that the neuronal expression and proteolytic 
A) 
B) 
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cleavage of the N-terminal region of PrPC is involved in myelin maintenance (Bremer 
et al., 2010); (Küffer et al. submitted). 
Apart from the generation of PrPC knock out mice, several other strategies including 
protein-protein interaction assays and genetic screenings have been used to unmask 
the physiological function of PrPC (Steele et al., 2007). However, most of the 
suggested functions remains controversial and the mechanisms behind the specific 
interactions are poorly understood (Steele et al., 2007) (see Table 5).  
An example is the suggested anti-oxidative function of PrPC (Steele et al., 2007). The 
OR region of Prnp is able to bind copper (Brown et al., 1997), and based on this 
observation, many studies have suggested a protective effect of PrPC against 
oxidative species (Roucou and LeBlanc, 2005; Steele et al., 2007). However, genetic 
ablation of PrPC in vivo shows no significant impairment of SOD activity and therefore 
contradicts this theory (Hutter et al., 2003). 
Another hypothesis is that PrPC regulates the circadian rhythm (Tobler et al., 1996). 
An altered circadian rhythm and sleeping pattern has been detected in PrPC knock 
out mice (Tobler et al., 1996; Huber et al., 1999). Dysregulation of the sleep-wake 
cycle and sleep reduction are characteristic features of fatal familial insomnia (FFI), 
an inherited form of prion disease (Gambetti et al., 1995; Montagna et al., 1995; 
Lugaresi et al., 1998; Montagna et al., 2003). Furthermore, sleep-wake disturbances 
similar to FFI have also been observed in CJD (Landolt et al., 2006). Other 
suggested functions include stem-cell renewal and proliferation of neuronal 
progenitors, neuronal excitability, cell signaling and neurogenesis (Steele et al., 
2007) (see Table 5). 
In summary, the most likely function of PrPC is neuroprotection, supporting the 
hypothesis that loss of function leads to cell death in prion disease. 
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Table 5: Examples of proposed functions of PrP based on PrP knock out mice 
Table modified from (Steele et al., 2007) 
Phenotype in PrP knock out mice Reference Confirmed? Opposing? 
Myelin maintenance 
chronic demyelinating polyneuropathy (Bremer et al., 2010) (Küffer et al., submitted); 
(Nuvolone et al., 2016) 
 
Circadian/Sleep regulation
Altered circadian rhythm (Tobler et al., 1996)   
Disturbance of sleeping pattern (Tobler et al., 1997)   
Neuronal excitability
Altered long term potentiation (Collinge et al., 1994) (Carleton et al., 2001; 
Herms et al., 2001; 
Curtis et al., 2003; 
Asante et al., 2004; 
Criado et al., 2005) 
(Herms et al., 1995; 
Lledo et al., 1996; Maglio 
et al., 2004; Maglio et al., 
2006) 
Enhanced susceptibility to seizures (Walz et al., 1999) (Rangel et al., 2007) (Striebel et al., 2013a; 
Striebel et al., 2013b) 
Neuroprotection
Increased susceptibility to ischemia (McLennan et al., 2004)   
Increased susceptibility to apoptosis caused 
by Ethanol 
(Gains et al., 2006)   
Increased susceptibility (Hoshino et al., 2003)   
Stem and precursor cells
Impaired self-renewal of stem cells (Zhang et al., 2006)   
Decreased proliferation of neuronal 
progenitors 
(Steele et al., 2006)   
 
6.2. PrPC neurotoxicity is mediated by the flexible tail 
The flexible tail of PrPC seems to play an essential role in prion pathogenesis. Prion 
or POM1 (an antibody against the globular domain of PrPC) mediated toxicity in 
organotypic cerebellar slices can be prevented by the application of an antibody 
targeting the OR within the flexible tail of PrP (POM2 antibody) (Sonati et al., 2013; 
Herrmann et al., 2015) (see Figure 19 A). This leads to the hypothesis that PrPC 
triggers cell death signaling via its flexible tail (see Figure 19 C). Moreover, depletion 
of this specific region ameliorates the pathology in prion infections (Flechsig et al., 
2000) (see Figure 19) and POM1 toxicity (Sonati et al., 2013). The octapeptide 
repeat insertion in the PRNP gene is responsible for inherited prion diseases such as 
GSS and CJD (Goldfarb et al., 1991; Mead et al., 2006; Kumar et al., 2011). 
Consistent with these findings is the observation that spontaneous 
neurodegeneration occurs in mice expressing the amino-terminal truncated PrPC 
(Shmerling et al., 1998) or a GPI-linked flexible tail (Dametto et al., 2015). 
Additionally, it has been found the OR of PrPC is the binding site for amyloid beta in 
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Alzheimer’s disease (Lauren et al., 2009; Zou et al., 2011). Several investigations 
indicate that PrPC is responsible for neuronal loss and memory deficits in Alzheimer’s 
disease (Larson et al., 2012; Um et al., 2012; Ostapchenko et al., 2013; Um and 
Strittmatter, 2013). Therefore, we decided to query whether PrPC could act as a 
general cell death transducer in neurodegenerative diseases (see Figure 19 D). As 
mentioned before, the N-terminal region of PrPC is essential for its neurotoxic 
function (Shmerling et al., 1998; Sonati et al., 2013; Dametto et al., 2015; Herrmann 
et al., 2015) .Accordingly, if PrPC acts as a cell death transducer, blocking this 
specific region could have a beneficial effect on neuronal viability, not only in prion 
infection and POM1 toxicity, but also against a general plethora of cell stressing 
agents that cause ER stress and neurotoxicity 
 
 A) Prion disease B) POM1 medated toxicity
Figure 18: Comparison of prion and POM1 mediated toxicity  
Prion disease (A) as well as in POM1 mediated toxicity (B) are both PrPC dependent, activate the PERK signaling 
branch of the UPR and have huge set of overlapping genes that are differently upregulated (Herrmann et al., 
2015). This suggest that POM1 is a good mimic of prion mediated toxicity (Herrmann et al., 2015). 
Image modified: (Herrmann et al., 2015) 
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A) B) 
 
 
 
 
 
 
 
 
 
C) D) 
 
 
 
 
 
 
 
 
Figure 19: Involvement of the flexible tail of PrPC in neurotoxic signaling  
Pre-incubation of POM2 A) that binds to the octapeptide region (OR) of PrPC or B) depletion of the OR region 
blocks POM1 mediated toxicity (Sonati et al., 2013). C) Therefore, Sonati et al. postulated that the flexible tail 
might be essential for the initiation of neurodegeneration in prion disease (Sonati et al., 2013). D) Based on this 
observation, it was hypothesized that PrPC could act as a general cell death transducer initiating cell death upon 
different cellular stressors like oxidative stress, ER stress and amyloid beta (Illustrations A-C modified (Sonati et 
al., 2013)). 
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6.3. ER homeostasis in neurodegenerative diseases 
In prion disease as well as in the POM1 mediated toxicity an upregulation of genes 
involved in the UPR (Unfolded Protein Response) are induced ((Sonati et al., 2013; 
Herrmann et al., 2015).  
 
6.3.1. Unfolded Protein Response is activated in response to ER stress 
ER stress can be triggered by a variety physiological and pathophysiological 
conditions that lead to the accumulation of misfolded proteins in the ER (Bravo et al., 
2013; Sano and Reed, 2013; Hetz and Mollereau, 2014). To counteract ER 
imbalance, the cell activates a mechanism called the UPR (Rao et al., 2004; Hetz 
and Mollereau, 2014). The three core signaling proteins of the UPR are inositol-
requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6) and protein kinase 
RNA-like ER kinase (PERK) (Hetz, 2012; Sano and Reed, 2013; Hetz and Mollereau, 
2014). All of these three ER membrane proteins bind to the Immunoglobulin Binding 
Protein (BIP (GPR78)), which is released into the cytoplasm during the UPR, where it 
assists in protein folding and thereby activates these three signaling branches (Hetz, 
2012). Initially ER stress leads to a translation stop, whereas specific proteins 
assisting in protein folding and ER-assisted degradation (ERAD) mediated protein 
decay are upregulated (Kim et al., 2008). If these mechanisms are not sufficient to 
restore ER homeostasis, cell death is initiated (Kim et al., 2008). 
The induction of IRE1 enables unconventional splicing of XBP1 mRNA (Yoshida et 
al., 2001; Uemura et al., 2009). The spliced from of the transcription factor XBP1 
activates genes involved in ERAD mediated decay, protein folding, lipid synthesis 
and other important processes of the UPR (Hetz et al., 2011). Upon ER stress, ATF6 
translocates to the Golgi, where it is activated (Hetz, 2012). The active fragment of 
ATF6 causes upregulation of genes encoding ERAD components and XBP1 (Hetz, 
2012). The autophosphorylation of PERK initiates the phosphorylation of eIF2α, 
which induces a general translational stop and upregulation of specific mRNA like 
ATF4 that results in cell death if ER stress persists (Hetz and Mollereau, 2014; Wang 
and Kaufman, 2016) (see Figure 20). 
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Figure 20: Activation of UPR via three main signaling pathways  
ER stress initiates the UPR via three main signaling branches activated by the transmembrane receptors IRE1, 
ATF6 and PERK (Bernales et al., 2012). The UPR tries to restore ER homeostasis via a global inhibition of 
translation and activation of translation of genes important for protein folding and ERAD degeneration (Bernales 
et al., 2012) (Illustration (Bernales et al., 2012)) 
 
6.3.2. Activation of ER stress in neurodegenerative diseases 
Despite the distinctive clinical and pathological features , neurodegenerative 
diseases such as Alzheimer disease, Huntington disease, amyotrophic lateral 
sclerosis (ALS) and prion disease share a common feature: the accumulation of 
abnormally folded proteins (Soto, 2003; Doyle et al., 2011). Therefore, these 
diseases are collectively referred to protein misfolding disorders (PMDs) (Chiti and 
Dobson, 2006). 
There is growing evidence that the neuronal losses in PMDs are caused by the 
disturbance of ER homeostasis, in particular, by malfunctions in the UPR (Hetz and 
Mollereau, 2014). Therefore, targeting the UPR may offer a new therapeutic option in 
PMDs (Hetz et al., 2013; Torres et al., 2015). However, caution is merited, since 
experimental data indicate  that different proteins involved in the UPR can have either 
protective or disease promoting function dependent on the PMD (Hetz et al., 2013; 
Hetz and Mollereau, 2014; Scheper and Hoozemans, 2015) (compare Table 6). 
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Table 6: Signaling pathways affected in PMD 
Signaling 
pathway 
PMD UPR 
marker 
Model system Effect Reference
IRE1 
pathway 
Prion disease XBP1 mouse ablation reveals no change in the disease phenotype (Hetz et al., 2008) 
Alzheimer’s disease 
IRE1 cell lines PS1 mutants compromise IRE1 signaling (Katayama et al., 2001) 
XBP1 human downregulated (Reinhardt et al., 2014) 
ALS XBP1 mouse ablation attenuates disease phenotype (Hetz et al., 2009) 
Huntington’s 
disease XBP1 mouse 
ablation attenuates disease 
phenotype (Vidal et al., 2012) 
PERK 
pathway 
Prion disease 
PERK 
elF2α mouse 
phosphorylated forms of 
PERK and eIF2α only 
detected in CJD inoculated 
mice with neurofibrillary 
pathology 
(Unterberger et al., 
2006) 
elF2α 
ATF4 
mouse 
brain slices 
Upregulation of P-elF2α and 
ATF4 (Herrmann et al., 2015) 
GADD34 mouse 
Decreased levels of 
GADD34 lead to continuous 
activation of elF2α 
(Moreno et al., 2012) 
Alzheimer’s disease PERK  
cell lines and 
primary cells 
PS1 mutant cause 
malfunction (Katayama et al., 2001) 
GADD34 mouse upregulation (Honjo et al., 2015) 
ALS 
PERK mouse 
Expression of a non-
functional form of PERK 
accelerates disease 
progression  
(Wang et al., 2011) 
ATF4 mouse ATF4 promotes disease progression (Matus et al., 2013) 
GADD34 mouse Prevention of upregulation of GADD34 is neuroprotective  
(Jaronen et al., 2013; 
Wang et al., 2014) 
Huntington’s 
disease ATF4 mouse 
ablation of ATF4 shows no 
difference in disease 
phenotype 
(Vidal et al., 2012) 
ATF6 
pathway 
Alzheimer’s disease ATF6 cell lines and primary cells 
PS1 mutations prevent 
activation of ATF6 (Katayama et al., 2001) 
ALS 
ATF6 cell lines VAPB prevents processing of ATF6 (Gkogkas et al., 2008) 
ATF6 human upregulation of ATF6 levels in spinal cord (Atkin et al., 2008) 
Huntington’s 
disease ATF6 mouse inactivation of ATF6 (Naranjo et al., 2016) 
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6.3.3. Therapeutic targeting of ER pathways in neurodegenerative diseases 
Attenuation of ER stress levels with pharmacological or gene therapy has been 
successful in reducing the pathological features in various animal models of 
neurodegeneration and thus holds promise as a therapeutic target for human 
neurodegenerative diseases (Kim et al., 2008; Hetz and Mollereau, 2014). 
For example, the PERK inhibitor GSK2606414 has been shown to ameliorate 
neuropathological and clinical signs of prion disease (Moreno et al., 2013). Despite 
the favorable bioavailability of this drug and observed therapeutic potential, 
GSK2606414 is far from being implemented as a treatment option because of severe 
side effects such as weight loss and mild hyperglycemia (Moreno et al., 2013). 
Another tested inhibitor is Salubrinal, which targets  the UPR by inhibition of the 
inactivation of eIF2α (Boyce et al., 2008). While the agent exhibits a protective effect 
in ALS (Saxena et al., 2009) and Parkinson’s disease (Colla et al., 2012), it seems to 
aggravate the disease phenotype in prion diseases (Moreno et al., 2012).  
Apart from small-molecule inhibitors, gene therapies have been tested as promising 
treatment in PMDs. In a mouse model of Huntington’s disease, overexpression of 
XBP1 leads to a decrease in mutant Huntingtin (Zuleta et al., 2012). Additionally, 
overexpression of GADD34 leads to a significant extension of the survival time in 
prion disease (Moreno et al., 2012). An overview of the aforementioned therapeutic 
interventions is provided in the table below. 
 
Table 7: Therapeutic targeting of the UPR in PMD 
Disease Model Agent Effect Reference 
Pharmacological approaches 
Prion disease mouse PERK inhibitor Decreased neurodegeneration, delayed 
disease progression (Moreno et al., 2012) 
Prion diseases mouse Salubrinal  Disease exacerbation (Moreno et al., 2013). 
ALS mouse Salubrinal Extended lifespan (Saxena et al., 2009) 
Gene therapy 
Huntington’s disease mouse AAV-XBP1s Reduction of mutant Huntingtin (Zuleta et al., 2012) 
Prion disease mouse LV-GADD34 Decreased neurodegeneration (Moreno et al., 2012) 
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6.4. Scientific Aims 
PrPC is mainly distinguished by its essential role in mediating neurodegeneration in 
prion disease (Bueler et al., 1993; Sailer et al., 1994). However, the molecular 
mechanisms that underlie the neuronal cell loss are still enigmatic (Aguzzi and 
Calella, 2009). Understanding the physiological function of prion protein may help 
unravel the pathophysiology of prion disease, which in turn may facilitate the design 
of effective therapeutic strategies. 
The aim of the project was to investigate the involvement of PrPC in neurotoxic 
signaling caused by ER stress. Our experimental setup included the following 
studies: 
 Study of the protective role of POM2, a N-terminal targeting anti-PrP 
antibody against ER stress. POM2 binds to the OR of the PrPC and is 
neuroprotective against POM1 and RML induced toxicity in cerebellar slices 
(Sonati et al., 2013; Herrmann et al., 2015). In addition, it has been suggested 
that the neuronal loss in prion disease is evoked by disturbed ER homeostasis 
(Xu and Zhu, 2012; Roussel et al., 2013). Therefore, we sought to evaluate 
the potential of this antibody to alleviate neuronal loss triggered by ER stress. 
Dependent on the PMD, different types of neurons have different levels of 
vulnerability and response to cell stress (Saxena and Caroni, 2011; Jackson, 
2014). Therefore, we utilized different types of neurons including moto-, inter- 
and granule neurons and pre-incubated with POM2 before stressor treatment. 
The extent of neuroprotection was measured by the morphological 
assessment of neurite outgrowth and the assessment of neuronal number with 
significant outgrowth. 
 Study of the potential of POM2 as a therapeutic target in animal models 
of neurodegenerative diseases. My preliminary data indicate that POM2 
delays ER stress in vitro and therefore might qualify as a useful therapeutic 
target of PMD. However, there were some indications that POM2 causes 
hemolysis ((Sonati et al., 2013) and unpublished data of Prof. Magda 
Polymenidou), an observation that would prohibit the application of POM2 via 
intravenous injection. In my experiments, I could confirm the aforementioned 
observations. As a result, it was decided to use an adeno-associated virus 
(AAV) expressing scFv POM2 for the therapeutic intervention in in vivo studies 
and the viruses were prepared in collaboration with Prof. Bernard Schneider. 
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 Evaluation of the protective potential of POM2 in vivo. Testing the 
therapeutic potential of the AAV expressing scFv POM2 in multiple animal 
models of neurodegenerative diseases. Since these experiments are tedious 
and time consuming and result in a severe phenotype (for example, 
Huntington’s or ALS disease models), it was decided to test the therapeutic 
potential of POM2 first in a rather simple in vivo system. Thus, the AAV 
expressing scFv POM2 was injected to the mouse eye prior to photo toxicity-
induced retinal neurodegeneration (collaboration Prof. Christian Grimm). 
 
6.5. Results 
6.5.1. In vitro model systems to explore the potential of PrPC as a general cell death 
transducer 
ER stress is a common feature of neurodegenerative diseases (Lindholm et al., 
2006; Doyle et al., 2011; Roussel et al., 2013). PrPC is involved in neurotoxic 
signaling in both prion (Bueler et al., 1993; Sailer et al., 1994) and Alzheimer disease 
(Kudo et al., 2013; Um and Strittmatter, 2013; Jarosz-Griffiths et al., 2016). We 
sought to test whether PrPC can act as a general cell death mediator. In order to test 
the latter, we utilized the protective POM2 antibody (Sonati et al., 2013; Herrmann et 
al., 2015) in mouse primary or ESC-derived neurons. In neurodegenerative diseases 
a distinct subset of neurons are usually affected, which defines the clinical symptoms 
(Saxena and Caroni, 2011; Jackson, 2014). Therefore, several neuronal 
subpopulations were used to check the ability of POM2 to counteract ER stress. 
Moto- and interneurons that are vulnerable to neuronal loss in ALS (Saberi et al., 
2015) and cerebellar granule neurons, which represent a major type of neuronal 
population affected in prion disease (Budka, 2003; Faucheux et al., 2009) were used 
(see Table 8).  
The ER stressor Tunicamycin (TM) was selected to assess the protective efficiency 
of the POM2 antibody. TM is a composite of different homologous nucleoside 
antibiotics (Price and Tsvetanova, 2007). It specifically inhibits N-acetylglucosamine 
transferases, which prevents the glycosylation of newly synthesized glycoproteins 
(Takatsuki et al., 1975; Tkacz and Lampen, 1975). This in turn disables the transport 
of those proteins from the ER to other cellular compartments, which results in local 
accumulation or ER stress (Oslowski and Urano, 2011). 
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Table 8: Types of neurons used for screening the protective effect of POM2 
Type of neuron Species Reflecting 
population 
affected in 
Fluorescent 
marker 
Image type 
used for 
analysis 
Comment
ESC-derived moto- and 
interneurons 
mouse ALS GFP expression 
under HB9 
promoter  
fluorescent 
images 
Derived from NT 
mESCs 
Primary granule neurons mouse Prion disease No bright field 
images 
From tga20 or ZH3 
pups 
 
Neurons were treated with different concentrations of TM selected according to 
previous publications (Galehdar et al., 2010; Nunziante et al., 2011; Dery et al., 2013; 
Kim et al., 2015a). 
For evaluation of neuroprotection, live cell imaging was performed with the Plate 
Runner (Trophos) or the IncuCyte (EssenBio). Compared to the Plate Runner 
(Trophos), which was described under 5.5.3.1, the IncuCyte has the advantage that 
reading can be done directly in the incubator, which avoids temperature fluctuations. 
Furthermore, up to six 96 well plates fit in the IncuCyte and the reading could be 
programmed accordingly. The moto- and interneurons expressed a fluorescent 
marker whereas the granule neurons were not fluorescently labeled. Therefore, for 
quantification of the moto- and interneurons, fluorescent live-images were used, 
whereas for the the data analysis of granule neurons were based on bright field 
images.  
 
Image analysis was performed with MetaMorph software. For quantification of the 
data, I focused on the cell number with significant outgrowth and changes in the 
neurite outgrowth, because these parameters exhibited the most significant changes 
upon stressor treatment (data not shown). 
 
6.5.1.1. Protective effect of POM2 against ER stress  
mESC derived moto- and interneurons, expressing wildtype PrPC, were co-cultured 
with primary tga20 astrocytes overexpressing PrPC. One day after plating the 
neurons, neuron-astrocyte co-cultures were incubated for 2 h with POM2 prior to ER 
stress induction. TM (1 ug/ml) treatment resulted in neuronal loss and a reduced 
neurite outgrowth in moto- and interneurons. This preliminary test showed a more 
profound stress effect of TM treatment on interneurons compared to motoneurons, as 
defined by increased neuronal loss and reduced neurite outgrowth. The application of 
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POM2 to interneurons did not reveal any protective effect against ER stress (see 
Figure 21 A and B). 12h after stressor treatment, we could observe a significant 
increase in the number of motoneurons with significant outgrowth, however, only in 
motoneurons pre-incubated with POM2 (see Figure 21).  
 
A) C) 
B) D) 
Figure 21: Evaluation of the protective potential of POM2 against ER stress in moto- and interneurons  
mESC derived moto- and interneurons were pre-incubated with POM2 (200 nM) for 2h prior to TM treatment 
(1 ug/ml). To evaluate cell viability, the cell number with significant outgrowth and the changes in the neurite 
outgrowth were analyzed in co-cultures of astrocytes with interneurons (A and B) or (C and D) motorneurons, 
respectively. Although TM induced significant changes in neuronal morphology in the interneuron-astrocytic co-
cultures (A and B), no protective effect of POM2 could be observed. In the motorneuron-astrocytic co-cultures (C 
and D), the morphological changes are less significant. 12h after stressor treatment, a significant increase in the 
number of motoneurons with significant outgrowth was observed, however, only in motoneurons pre-incubated 
with POM2. Each error bar indicates average SD of 4-5 technical replicates. The two-way ANOVA with Bonferroni 
post-test was used for this experiment (compared groups: Untreated-POM2, untreated-TM, TM-POM2+TM) 
(p < 0.0001 = ****, p < 0.001 = ***, p < 0.01 = **, p < 0.1 = *) 
 
The next step was to elucidate the protective potential of POM2 in pure granule 
neurons. In contrast to the previous studies where neuron astrocyte co-cultures were 
used, the use of pure neuronal cultures excludes any non-cell autonomous effect due 
to glial cells. In these granule neuronal cultures, POM2 was shown to have a positive 
effect on TM treated cells, although a complete rescue from the toxic effect of the 
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stressor could not be observed. It appears that POM2 exerts its protection by 
delaying the induction of ER stress and neurodegeneration. 
Compared to motoneurons in co-culture with astrocytes, the protective potential is 
much more significant, which might be also due to the fact that neurons overexpress 
PrPC. In addition, increased neurite degeneration upon TM treatment could be seen, 
which is most likely accounted for by the 10 times higher TM concentration and the 
absence of astrocytes. 
 
A)  
Tga20 Cerebellar Granule Neurons 
B) 
Tga20 Cerebellar Granule Neurons 
Figure 22: POM2 delays ER stress induced cell death in primary tga20 cerebellar granule neurons 
A)+B) 5 day old primary tga20 granule neurons were exposed to POM2 (200 nM) 2 h before treatment with TM 
(10 ug/ml). The toxic effects of TM were ameliorated in cells pre-treated with POM2. Application of POM2 delays 
the reduction in the number of cells with significant outgrowth as well as neurite outgrowth in ER stress induced 
neurons. Each error bar indicates the average SD of 5 technical replicates. The two-way ANOVA with Bonferroni 
post-test was used for this experiment (compared groups: Untreated-POM2, untreated-TM, TM-POM2+TM) (p < 
0.0001 = ****, p < 0.001 = ***, p < 0.01 = **, p < 0.1 = *). 
 
6.5.1.2. The protective effect of POM2 is PrPC dependent  
To confirm that the protective effect of POM2 treatment against cellular stress/cell 
death is dependent on the expression of PrPC, I performed the same experiment in 
ZH3 primary granule neurons that do not express PrPC. POM2 was not able to 
induce significant changes in the cells, suggesting that the effect indeed is PrPC 
dependent. 
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A)  
ZH3 Cerebellar Granule Neurons 
B)  
ZH3 Cerebellar Granule Neurons 
Figure 23: Protective effect of POM2 is PrPC dependent 
5 day old primary neurons of PrPC knock out mice (ZH3) were pre-incubated with POM2 2h before the application 
of TM (200 nM). POM2 treatment had no influence on the cell number with significant outgrowth or on changes in 
neurite outgrowth. Each error bar indicates the average SD of 5 technical replicates. The two-way ANOVA with 
Bonferroni post-test was used for this experiment (compared groups: Untreated-POM2, untreated-TM, TM-
POM2+TM) (p < 0.001 = ****, p < 0.001 = ***, p < 0.01 = **,  
p < 0.1 = *). 
 
6.5.1.3. Investigation of translational changes after ER stress of POM2 pre-incubated 
cells  
My preliminary data suggest that POM2 is able to delay neuronal toxicity triggered by 
ER stress. To address this observation in a human physiological context, iPSC 
derived human pan-neurons were used. In an initial approach, human neurons were 
pre-incubated for 2 h with POM2 before the application of TM (10 ug/ml). As a 
control, POM2 was inhibited with the addition of the PrP fragment P20 (Polymenidou 
et al., 2008). This peptide contains the binding region of POM2 and should prevent 
the interaction of POM2 with PrPC. After 24 h the protein was collected and changes 
in the expression level of several proteins were analyzed. 
Interestingly, PrPC levels are highly upregulated upon induction of ER stress as 
previously shown (Dery et al., 2013; Misiewicz et al., 2013). However, no changes in 
the PrPC expression level upon POM2 treatment were detected (see Figure 24 A). 
In Alzheimer’s disease, changes in synaptic plasticity can be evoked via ER stress 
(Endres and Reinhardt, 2013; Duran-Aniotz et al., 2014). In particular, synaptic 
degradation is associated with the activation of Fyn through the coupling of Aβ 
oligomers with the mGluR5-PrPC complex (Um and Strittmatter, 2013; Nygaard et al., 
2014). There are also several indications that PrPC leads to an activation of Fyn via 
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the plasma membrane protein caveolin-1 (Mouillet-Richard et al., 2000; Toni et al., 
2006; Shi et al., 2013). It seems that the octapeptide-region of PrPC is especially 
important for this interaction (Shi et al., 2013). This is the binding region of the POM2 
antibody (Polymenidou et al., 2008) suggesting a potential role of POM2 in the Fyn 
pathway. Caveolin-1 and P-Fyn levels were analyzed to examine the impact of 
POM2 on Fyn signaling. However, there were no obvious changes after TM 
treatment and a POM2 specific effect could not be observed (see Figure 24 B, C). 
The UPR caused by ER stress leads to an induction of ERK1/2 (mitogen-associated 
protein kinases (MAPK) p42/44) (Darling and Cook, 2014), which was identified as a 
downstream target of the Fyn pathway (Schneider et al., 2003). In prion infected mice 
(LaCasse et al., 2008) and cell lines, ERK1/2 is activated (Didonna and Legname, 
2010; Pradines et al., 2013). As expected, human neurons treated with TM showed 
phosphorylation of ERK1/2; however, there was no indication that POM2 could 
prevent this (see Figure 25 D). 
BiP is a master regulator of the UPR (Wang et al., 2009; Wang et al., 2010b). It has 
been shown that the disease associated mutant (Q217R) (Jin et al., 2000) as well as 
the flexible tail of PrPC (FTgpi) interacts with BiP (Dametto et al., 2015). Since PrPC 
interacts with BiP, I checked the regulation pattern of BiP upon POM2 treatment. BiP 
was upregulated in neurons treated with TM; however, POM2 could not prevent the 
induction of protein expression. Alternatively, POM2 pre-incubated with P20 and P20 
alone resulted in a slightly decreased signal (see Figure 25 E). 
The transcription factor CCAAT-enhancer-binding protein homologous protein 
(CHOP) is significantly upregulated after the induction of ER stress (Cheng and Yeh, 
2003; Reimertz et al., 2003) and CHOP signaling seems to be implicated in many 
PMDs, for example upregulation of CHOP was observed in ALS and Alzheimer’s 
patients and mouse models (Milhavet et al., 2002; Ito et al., 2009; Lee et al., 2010; 
Sasaki, 2010). While the transduction of CHOP in Huntington disease patients was 
increased (Vidal et al., 2012), no changes were observed on the protein level 
(Carnemolla et al., 2009). A significant increase in the expression levels of CHOP 
was triggered upon treatment with the ER stressor TM. Pre-incubation of the cells 
with POM2 did not lead to a decrease in the CHOP signal (see Figure 25 F). 
At least for the proteins tested, POM2 did not reveal any beneficial effect. However, 
based on the morphometric analysis POM2 was able to delay the neurite 
degeneration induced by ER stress. It is suggested that PrPC can promote neurite 
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outgrowth via interaction of different proteins such as laminin (Graner et al., 2000b; 
Graner et al., 2000a; Coitinho et al., 2006; Beraldo et al., 2011; Santos et al., 2013), 
vitronectin (Hajj et al., 2007), NCAM (Santuccione et al., 2005) stress-inducible 
protein-1 (STI-1) (Lima et al., 2007; Santos et al., 2013) and even PrPC itself (Chen 
et al., 2003). On the other hand inhibition of neurite outgrowth was observed by the 
interaction of PrPC with contactin-associated protein (Caspr) (Devanathan et al., 
2010). Thus interaction of POM2 with PrP might interfere with neuritogenesis 
signaling. 
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A) B) C) 
PrPC Caveloin-1 P-Fyn 
 
 
 
 
 
 
 
   
Figure 24: Expressional changes of PrPC, Caveloin-1 and P-Fyn in TM treated human pan-neurons pre-incubated with POM2 
iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 (400 nM) 2h before induction of ER stress with TM (10 
ug/ml). After 24h the protein was isolated and expression levels of PrPC, P-Fyn and Caveloin-1 were examined (1 replicate was used per condition). 
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A)  B)  C) 
P-Erk1/2 BiP CHOP 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 25: Expressional changes of P-Erk1/2, BiP and CHOP in TM treated human pan-neurons pre-incubated with POM2 
iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 (400 nM) 2h before induction of ER stress with TM  
(10 ug/ml). After 24h the protein was isolated and expression levels of P-Erk1/2, CHOP and BiP were examined (1 replicate was used per condition). 
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I changed the treatment conditions in order to reveal translational changes upon 
POM2 treatment in iPSC derived human neurons that have undergone ER stress. 
Based on previous data obtained from primary cerebellar granule neurons treated 
with TM, it appears that POM2 is delaying cell death rather than inducing a complete 
rescue. Therefore, I decided to assess the time course of the expression level of 
selected proteins involved in ER stress. 
The experimental settings were adjusted in order to improve the effect caused by 
POM2. In particular, the incubation time of POM2 before the stressor treatment was 
decreased from 2 to 0.5 h to reduce the amount of antibody that is degraded or 
endocytosed at the time the stressor is added. Furthermore, a lower concentration of 
TM was applied to decrease the toxic effect and the ER stressor Thapsigargin (TH) 
was applied. TH leads to a depletion of calcium in the ER and an upregulation of 
extra-cellular calcium via the inhibition of the sarcoplasmic/endoplasmic reticulum 
calcium ATPase (SERCA) (Treiman et al., 1998). After stressor treatment, the protein 
was collected at 3, 6 and 9 h time points. 
The levels of PrPC, BiP and CHOP were rechecked. In addition, the expression levels 
of the transcription factor ATF4 were analyzed. Studies of Galehdar et al. in primary 
mouse cortical neurons reveal that after TM and TH application, ATF4 is markedly 
upregulated and the depletion of ATF4 leads to significantly increased survival 
(Galehdar et al., 2010). In addition, enhanced translation of ATF4 was shown in RML 
inoculated and POM1 treated brain slices (Herrmann et al., 2015), as well as in 
Alzheimer’s disease patients and mouse models (Ma et al., 2013; Baleriola et al., 
2014; Wei et al., 2015). 
In the following figures, the western blots at the 3h, 6h and 9h time points and the 
time course of the protein level for the selected proteins are depicted.  
At the 6h time point an increase in the PrPC levels only in the sample treated with 
500 nM TH was observed while pre-incubation of POM2 and POM2 plus P20 block 
this effect. However, for other time points, no conclusive pattern could be observed 
(see Figure 26). 
The protein level of BiP for each time point is lower in the POM2 or POM2 plus P20 
treated cells than in the control. After TM treatment no upregulation of BiP could be 
observed for the 3 and 6h time point and after 9h the BiP levels in the untreated 
samples are higher than the control (see Figure 27). This suggests that TM did not 
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cause ER stress or the ER was too weak to activate the BiP after this time frame. 
After 3h for both concentrations of TH, the levels of BiP were increased. At this time 
point POM2 and POM2 plus P20 could decrease the BiP signal. Given that P20 
should prevent the effect of POM2, the observed downregulation of BiP in this control 
samples could only be attributed to insufficient blocking of POM2 with P20. The lower 
concentration of TH caused a stronger increase in the BiP signal at the 3h time point, 
while at the 6h and 9h time points, no dramatic difference was observed between the 
BiP levels. In particular, at 6h the pre-incubation of POM2 in the 250 nM TH treated 
neurons revealed a significant decrease of BiP that might be due to a protective 
effect of POM2. However, further experiments are needed to confirm these 
preliminary data. 
For the TH treated samples, a clear upregulation of ATF4 and CHOP could be 
observed for all time points, whereas the concentration of TM used was not able to 
induce upregulation of these UPR markers. At 3 and 6 hours after TH treatment, the 
translational level of ATF4 and CHOP was lower in the POM2 /TH treated cells than 
in the neurons treated only with TH. At the 9h time point, the signal of ATF and 
CHOP also increased in TH/POM2 treated samples (see Figure 28 and Figure 29). 
These results suggest a delay in UPR upregulation caused by POM2 treatment. 
Again, more replicates are needed for a more conclusive statement. 
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 PrPC  
A) 
3h 
 
 
 
B) 
6h 
 
 
C) 
9h 
 
 
D)    
TM (1 ug/ml) TH (250 nM) TH (500 nM)  
 
  
Figure 26: Time course of PrPC expression levels in ER stress induced human pan-neurons pre-incubated with POM2 
A)- D) iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 for 0.5 hours before the treatment of TM (1 ug/ml) or TH (250 nM 
or 500 nM). After 3h, 6h and 9h the protein was collected and the translational level of PrPC determined (per condition, 1 replicate was used). A)-C) The bands at 25 and 50 kDa are derived from 
the heavy and the light chain of the POM2 antibody. 
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Figure 27: Time course of BiP expression levels in ER stress induced human pan-neurons pre-incubated with POM2 
A)- D) iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 for 0.5 hours before the treatment of TM (1 ug/ml) or TH (250 nM 
or 500 nM). After 3h, 6h and 9h the protein was collected and the translational level of BiP determined (per condition, 1 replicate was used). 
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Figure 28: Time course of ATF4 expression levels in ER stress induced human pan-neurons pre-incubated with POM2 
A)- D) iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 for 0.5 hours before the treatment of TM (1 ug/ml) or TH (250 nM 
or 500 nM). After 3h, 6h and 9h, the protein was collected and the translational level of ATF4 determined (per condition, 1 replicate was used). 
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Figure 29: Time course of CHOP expression levels in ER stress induced human pan-neurons pre-incubated with POM2 
A)- D) iPSC derived human pan-neurons were pre-incubated with POM2 (200 nM), P20 (400 nM) and POM2 (200 nM) plus P20 for 0.5 hours before the treatment of TM (1 ug/ml) or TH (250 nM 
or 500 nM). After 3h, 6h and 9h, the protein was collected and the translational level of CHOP determined (per condition, 1 replicate was used). 
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6.5.2. In vivo models to test the therapeutic effect of POM2 
To evaluate if PrPC can act as a general cell death transducer in different 
neurodegenerative diseases, the therapeutic potential of POM2 should be evaluated 
in several animal models of neurodegenerative diseases. 
 
6.5.2.1. Establishment of an application method for POM2 in in vivo experiments 
Injection of POM2 in tga20 mice was shown to be lethal (Polymenidou, unpublished 
data). In vitro data suggest that POM2 leads to lysis of red bloods cells in a PrPC 
dependent manner through complement activation (Sonati et al., 2013). 
If POM2 would indeed cause hemolysis, in vivo application of the POM2 holo 
antibody would not be possible. Therefore, the intravenous injection of the POM2 
holo antibody in mice was repeated to exclude any contamination in the antibody 
preparation had caused this effect in previous results.  
The POM2 antibody was injected into three different genotypes expressing different 
levels of PrPC to evaluate if POM2 induces hemolysis in a PrPC dependent manner. 
In particular, ZH3 (PrPC knock out), C57BL/6J (PrPC wildtype) and tga20 mice (PrPC 
overexpressing) were intravenously injected with 100 ul antibody solution 
(concentration = 1ug/ul) of the POM2 holo antibody or the negative control mouse 
IgG. After 1h blood was collected in BD microtainer SSTTM tubes for serum collection. 
In addition, 1 day before the experiment and 5 min after injection of the antibody 
solution, blood was drawn into EDTA coated tubes. 
The serum of tga20 mice injected with POM2 showed a much stronger red coloration 
than other samples, which suggested that hemolysis had been induced (see Figure 
30).  
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Figure 30: POM2 causes hemolysis in PrPC overexpressing mice after 1h in vivo 
ZH3 (PrPC knock out; #1-2), C57BL/6J (PrPC wildtype; #3-4) and tga20 mice (PrPC overexpressing; #5-8) were 
injected with 100 ul (1 ug/ul) antibody solution of POM2 or IgG. After 1h blood was collected in BD microtainer 
SSTTM tubes to achieve serum. Only the serum of PrPC overexpressing mice (# 7 and 8) showed an intensive red 
color suggesting that hemolysis had occurred. 
 
For quantification of the hemoglobin concentration in serum, the toluidine assay was 
used (Goyal and Basak, 2009). The principle of this assay as follows: hemoglobin 
converts hydrogen peroxide to water and nascent oxygen (Goyal and Basak, 2009). 
The nascent oxygen then oxidizes yellow ortho-toluidine to a green blue reaction 
product (Goyal and Basak, 2009). The kinetics of the reaction is monitored at an 
absorbance of 630 nm, whereby the conversion rate to ortho-toluidine is directly 
proportional to the haemoglobin concentration (Goyal and Basak, 2009). The 
quantification of the hemoglobin in the serum indicates that POM2 induces hemolysis 
in mice overexpressing PrPC.  
 
 
Figure 31: Conversion of ortho-Toluidine to para-Toluidine catalyzed by hemoglobin 
Hemoglobin converts hydrogen peroxide to water and nascent oxygen, which in turn oxidizes ortho-toluidine to 
para-Toluidine. 
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Hemoglobin concentration in serum 
 
Figure 32: POM2 causes hemolysis in PrPC overexpressing mice after 1h in vivo 
PrPC depleted (ZH3), PrPC wild type (B57BL/6J) and PrPC overexpressing (tga20) mice were intravenously 
injected with 100 ul IgG or POM2 (1 ug/ul) solution. After 1h blood was collected and serum isolated. The 
hemoglobin concentration in the serum was determined with the o-Toluidine assay. For the ZH3 and B57BL/6J 
samples, one mouse was injected per antibody solution, and for the tga20 samples, two mice were injected per 
antibody solution. 
 
6.5.2.2. Generation of an Adeno associated virus expressing scPOM2  
The POM2 holo antibody causes hemolysis and cannot be administered 
intravenously. It is assumed that hemolysis is mediated by complement activation. 
Antibodies can cause complement activation via their Fc region (Noris and Remuzzi, 
2013; Melis et al., 2015). Therefore, it was decided to use the scFv POM2 for the 
planned in vivo studies. The use of the scFv antibody fragment is hampered by the 
fact that these fragments are not very stable in vivo (Worn and Pluckthun, 2001). To 
circumvent this issue, an Adeno associated virus (AAV) that allows the continuous 
expression of the antibody fragment in vivo was generated and the virus was 
prepared in collaboration with Prof. Dr. Bernard Schneider. Helper plasmids for the 
virus production were provided by Bernard Schneider and plasmids containing the 
scFv POM2 were designed and made by Dr. Vijay Chandrasekar. Since the virus will 
be applied to animal models of neurodegenerative diseases, a general promoter 
(cytomegalovirus (CMV)) was used for the scFv POM2 expression. Compared to a 
neuron specific promoter, this has the advantage that significantly more cells can be 
transduced and neuronal cell loss will not heavily affect the expression of scFv 
POM2. The Kozak sequence will be recognized by the ribosome and leads to an 
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enhanced translation initiation (Nakagawa et al., 2008). The BM40 signal peptide 
sequence ensures the secretion of scFv POM2, which allows a wide spread 
distribution of the therapeutic agent. The attachment of the His-Tag enables 
detection of the scFv POM2 after secretion. The internal ribosome entry side (IRES) 
sequence allows the initiation of translation within the mRNA (Komar and Hatzoglou, 
2011; Thompson, 2012) and is used to express the fluorescent marker tdTomato to 
track the expressing of the antibody. 
 
A)                                                Vector for scFv POM2 
 
 
B) 
Insert scFv POM2 
 
CMV 
 
Kozak BM40 scFvPOM2 
His 
Tag 
STOP IRES 
 
tdTomato 
   
  
Figure 33: scFv POM2 plasmid for AAV production 
A) The vector pAAV-CAG-tdTomato was cut on the BamHI and KpnI position. B) The scFv POM2 insert was 
cloned into the linearized vector. 
 
6.5.2.2.1. Transduction efficiency of Adeno associated virus ex vivo 
Virus production was done at the lab of Prof. Bernard Schneider. In a first trial it was 
planned to use the viral expression of scFv POM2 in a model of photoreceptor 
induced toxicity in the mouse eye detailed under 6.5.2.2.2. Therefore, it was decided 
to use the AAV8 serotype for our experiments. This serotype is especially suitable for 
a high transduction rate in the mouse retina. 
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AAV8 is not suitable for transducing cell lines or primary cell cultures according to 
Prof. Bernard Schneider. Therefore, we tested the expression of the virus in 
cerebellar organotypic brain slices of C57BL/6 mice. 
For long term survival of organotypic brain slices, cultivation at an air/liquid interface 
is crucial (Gahwiler, 1981; Gahwiler et al., 2001). This can be achieved either by 
culturing of the slices on semiporous membranes (Gahwiler, 1981) or by rotating 
them in a roller-tube filled with a small amount of medium (Gahwiler et al., 2001) (see 
Figure 34). We expected that the transduction potential of AAV is higher in roller-
tubes based on the continuous movement of the media over the slices. In addition, 
live imaging is less cumbersome, since the coverslip can be just placed under the 
microscope and cutting of the membrane is not necessary, which might otherwise 
destroy the slices. 
In brief, two cerebellar slices were embedded in a plasma clot on a glass coverslips 
and medium containing AAV8 expressing scPOM2 were added. Control slices were 
treated with AAV6 expressing GFP under the synapsin promoter. The use of a 
different serotype was based on the fact that the AAV6 was already shown in the lab 
to transduce slices efficiently. For the transduction of mouse brain slices with AAV8 
no significant results have been published. For the AAV6 at titer of 108 and 109 and 
for the AVV8 a titer of 109, 1010 and 1011 was used. After 1h of incubation at 4 °C the 
tubes were put into the rotating wheel within the incubator and viral expression was 
tested after 10 days. 
 
 
Figure 34: Cultivation of brain slices in roller tubes 
A) Glass coverslips were mounted with brain slices, which were imbedded in a plasma clot. B) These coverslips 
were then put in a roller tube with a small amount of medium, a plastic culture tube that has a flat-sided bottom. 
C) For cultivation of the brain slices, the tubes were put in a special incubator containing a slow rotating wheel 
that allows the alternation of aeration and nutrition of the slice (images modified (Gahwiler et al., 2001)). 
A) 
B) 
C) 
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10 day after infection, significant transduction of all slices with different titers of AAV8 
scFv POM2 or AAV6 GFP could be observed (see Figure 35). In general, AAV6 
seem to infect mostly the granule layer, while the AAV8 mainly transduces the 
molecular layer.  
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Figure 35: Cerebellar brain slices transduced with AAV8 
Cerebellar brain slices were transduced with A) AVV6 GFP or B) AAV8 scFv POM2 (titer = e109) and cultured in 
roller-tubes. 10 days after transduction slices were imaged. The AAV6 infected mostly the granule layer while the 
AAV8 revealed the strongest signal in the periphery. 
 
I have shown that the AAV8 scFv POM2 is able to transduce slices. The secretion 
levels of scFv POM2 are also important for the success of our studies. Therefore, to 
quantify scFv POM2 levels, the medium of the infected slices were collected and 
scFv POM2 expression was assessed by ELISA with the help of Rita Moos. Since 
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scFv POM2 design has a His-Tag, this was used for Biotin-Streptavidin-HRP 
detection of the scFv (see Figure 36). 
 
 
Figure 36: Principle ELISA for scFv POM2 detection 
Microtiterplates were coated with rPrP (1) and medium containing scFv POM2 were added (2). The scFv POM2 
contained a His-Tag. This was used for binding of a biotin conjugated antibody (3). Streptavidin coupled with 
horse radish peroxidase (HRP) were binding to biotin (4). The addition of the HRP substrate 3,3′,5,5′-
tetramethylbenzidin (TMB) allowed the indirect detection of the antibody (5). 
 
Three different titers of AAV8 scFv POM2 were used. The expression of scFv POM2 
was dependent on the titer. As expected, the slices not infected with virus or 
transduced with the control AAV6 GFP revealed no specific signal. As a positive 
control, scFv POM2 produced in bacteria was used. However, the detected 
concentration was higher than the applied one. The explanation for that observation 
might be a calculation error or the fact that the titration curve was solved in TopBlock 
and the scFv POM2 was diluted in slice culture media. 
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Secretion levels of scFv POM2 in cerebellar slices 
 
Figure 37: Quantification of secreted scFv POM2  
On day 1 cerebellar slices of C57BL/6 mice were infected with AAV8 scFv POM2 (titer: 1e9, 1e10, 1e11) and AAV6 
GFP (titer: 1e8, 1e9) or left untreated (PBS). 7 days after medium change (day 9-16), the medium was collected 
and scFv POM2 levels were detected via ELISA. Only AAV8 scFvPOM2 transduced slices efficiently and 
expresses the antibody in a titer dependent manner. The additional control, scFv POM2, which was produced in 
bacteria, gave a convincing signal. The explanation for that observation might be a calculation error or the fact 
that the titration curve was solved in TopBlock and the scFv POM2 was diluted in slice culture media. 
 
To achieve a therapeutic effect after POM2 treatment, a certain amount of scFv 
POM2 must be secreted. Therefore, the molarity of scFv POM2 per slice was 
calculated. Recently it was shown that the incubation of 6-10 slices with 335 nM (34 
to 56 nM/slice) of the holo POM2 antibody counteracts the neuronal loss in RML 
infected slices. The transduction of the slices with AAV8 scFv POM2 give values from 
113 to 451 nM scFv POM2/slice. Therefore we assume that this concentration is 
sufficient for therapeutic treatments, despite the fact that scFv fragments are less 
stable than holo antibodies (Worn and Pluckthun, 2001). 
Table 9: Amount of secreted scFv POM2 in AAV8 scFV transduced slices 
virus titer final ng/ml nMol/two slices nMol/slice 
scFv POM2 AAV8 1e11 253 902 451 
scFv POM2 AAV8 1e10 119 425 212 
scFv POM2 AAV8 1e9 64 227 113 
 
6.5.2.2.2. Therapeutic effect of POM2 against photoreceptor-toxicity in the mouse eye 
To check if PrPC can indeed act as a death sensor in neurodegenerative diseases, 
the protective potential of the AAV8 expressing scFv POM2 should be tested in 
animal models of neurodegenerative diseases. However, the evaluation of scFv 
POM2 as a therapeutic tool in mouse models will likely prove to be quite time 
consuming, because it would mandate behavioral studies and the specific handling of 
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animal models with specific neurodegenerative phenotypes. In addition, these 
studies are quite expensive. Therefore, we decided to initially test the protective 
potential of the scFv POM2 antibody in a simpler in vivo model system. The induction 
of photoreceptor apoptosis by light in the mouse eye seems to represent an 
appropriate system. In prion inoculated mice and hamster, apoptosis mediated 
neuronal loss in the retina could be detected (Hogan et al., 1981; Kozlowski et al., 
1982). Thus PrPC expression in the eye seems to play an important role in mediating 
cell death in neuronal cells in the retina after prion infection. If PrPC is a general cell 
death transducer, it is likely that it is also involved in mediating neurodegeneration 
induced by phototoxicity. Another advantage of this model system is the fast readout 
with results obtained in less than one month. 
In collaboration with Prof. Dr. Christian Grimm, the protective potential of scFv POM2 
against retina degeneration caused by phototoxicity was tested. For this experiment 
wild type BALB/c mice from Harlan and PrPC knock mice (Bueler et al., 1992) on a 
BALB/c background were used (Frigg et al., 2006). Mice with this genetic background 
were selected because they are homozygous for the retina pigment epithelial protein 
Rpe65450Leu (Frigg et al., 2006). The RPE65 gene is involved in rhodopsin 
regeneration in the retina (Redmond et al., 1998) and mice expressing the 
Rpe65450Leu are more vulnerable to light induced degeneration of the retina (Danciger 
et al., 2000; Wenzel et al., 2001). Before inducing phototoxicity, the mouse eye was 
infected with the AAV8 expressing the scFv POM2 via intravitreal injection. To ensure 
a stable expression of the virus, mice were kept for two weeks before phototoxicity 
was induced via light exposure. A light dose of 10’000 lux for 2h was used to induce 
strong photoreceptor apoptosis. 10 days after the induction of the neuronal loss, the 
mice were sacrificed and the retina collected. 
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Figure 38: Experimental setup of protective of POM2 against the phototoxicity in the retina 
Before the study started, mice were kept in a 12 h:12 h light/dark cyle. The mouse retina was transduced with 
AAV8 expressing scFv POM2 via intravitreal injection of the virus. To ensure a stable expression of the AAV mice 
were kept for 2 weeks. Prior to induction of the retinal degeneration with 10’000 lx for 2h mice were placed over 
night into a dark environment. After light exposure, mice were immediately returned to the 12 h:12 h light/dark 
cycle and sacrificed after 10 days. 
Image intravitreal injection: https://www.sec.gov/Archives/edgar/data/1273636/000119312514094588/g615962g94h06.jpg 
 
The virus should secrete scFv POM2 and express tdTomato in the cytoplasm. The 
expression of the virus was expected in retinal ganglion and the Müller glial cells 
(Lebherz et al., 2008; Schon et al., 2015). However, in cryosections of the retina no 
tdTomato fluorescence was detected. As a His-Tag is attached to the scFv POM2, I 
stained the retina with an anti-His-Tag antibody to detect the expression of the scFv 
POM2. From previous studies, it was expected that the AAV would transduce 
ganglion glial and Müller cells (Lebherz et al., 2008; Schon et al., 2015). None of this 
cell types were infected and show tdTomato. Independent from the infected cells, a 
rather unspecific staining was visible in the retinal periphery (see Figure 39). 
However, as mentioned before, the antibody should be secreted. Therefore, it was 
expected that most of the antibody is present extracellularly and it is not surprising 
that this method did not lead to a specific signal.  
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Figure 39: Absence of tdTomato expression in transduced retinas 
Cryosections of the mouse eye 24 days after intraventricular injection of A) PBS or B) the AAV8 scFv POM2. It 
was expected that the AAV will transduce ganglion glial cells in the GCL and Müller cells in the IPL. In both cases 
a rather unspecific staining of the RPE was obtained, which suggests that the His-Tag staining is not specific. 
RPE: retina pigmented epithelium; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; 
IPL: inner plexiform layer; GCL: ganglion cell layer. 
 
Despite the absence of significant viral scFv POM2 expression in the eye, retinal 
sections were analyzed. The retina morphology of the different samples was 
compared to evaluate if POM2 influences the light induced photoreceptor apoptosis. 
The untreated mouse eyes of both genotypes that were injected with PBS only 
revealed an intact retinal morphology (see figure A, C, E, G). Depletion of the 
photoreceptors suggested a severe phototoxicity in the Balb/c mice, which could not 
be rescued via the injection of the AAV8 scFv POM2 (see figure C, D). Interestingly, 
no PrPC dependent effect could be observed comparing Balb/c and PrP0/0 Balb/c 
mice after light induced photoreceptor apoptosis (see figure G, H). This result 
contradicts the previous finding that PrPC has a protective effect against light induced 
photoreceptor apoptosis. Most likely this is caused by the different experimental 
setup. In this experiment a relatively strong light exposure (10’000 lux, 2h) was used 
compared to the mild induction of phototoxicity (5’000 lux, 10 min) in the previously 
published experiment. In addition, the induced photoreceptor mediated apoptosis 
was so strong that hardly any photoreceptor cells remained. Based on this 
experimental setup, it could not be evaluated if PrPC is capable of promoting light 
induced apoptosis and scFv POM2 can be used for neuroprotection.  
DAPI, His-Tag  bright field     merge 
DAPI, His-Tag  bright field     merge 
Potential function of PrPC as a cell death transducer 
87 
 A)  Balb/c; PBS, control B)  Balb/c; PBS, 10'000 lux, 2h 
 
RPE 
 
 
 
ONL 
 
 
 
INL   
 C)  Balb/c; AAV8 scFv POM2, control D) Balb/c; POM2,10’000 lux, 2h 
 
RPE 
 
 
 
ONL 
 
 
 
INL   
 E) PrP0/0 BALB/c; PBS, control F) PrP0/0 BALB/c; AAV8 scFv POM2,  
10'000 lux, 2h 
 
RPE 
 
 
 
ONL 
 
 
 
INL   
 G) PrP0/0 BALB/c; AAV8 scFv POM2,  
control 
H) PrP0/0 BALB/c; AAV8 scFv POM2,  
10'000 lux, 2h 
 
RPE 
 
 
 
ONL 
 
 
 
INL   
Figure 40: Infection withAAV8 scFv POM2 could not ameliorate light-induced photoreceptor apoptosis  
Intravitreal injections with AAV8 scFv POM2 or a mock injection with PBS were done in BALB/c or PrP0/0 BALB /c 
mice. After 14 days phototoxicity was induced and 10 days later, the retina was collected. (A, C, E, G) BALB /c or 
PrP0/0 BALB/c mice show normal retina morphology independent of whether AAV8 scFv POM2 or PBS was 
injected. (B, D) The light dose of 10’000 lux for 2h caused severe toxicity in BALB/c mice. No protective effect of 
scFv POM2 could be observed. (G, H) The ablation of PrPC did not reveal any difference in cell morphology. 
Purple dotted lines label photoreceptor containing areas.  
RPE: retinal pigment epithelium, ONL: outer nuclear layer, INL: inner nuclear layer 
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6.6. Discussion 
Recently, it has been shown that POM2, an antibody binding to the N-terminal region 
of PrPC, counteracts neurodegeneration in prion infected and POM1 (a toxic antibody 
targeting the globular domain of PrPC) treated brain slices (Sonati et al., 2013; 
Herrmann et al., 2015). In both model systems, proteins involved in the PERK 
signaling branch of the UPR are downregulated upon POM2 treatment (Herrmann et 
al., 2015). ER stress induces the UPR in many PMD’s (Hetz and Mollereau, 2014). In 
addition, it has been discovered that PrPC is involved in synaptic degeneration in 
Alzheimer’s disease (Lauren et al., 2009). Therefore, it is assumed that PrPC could 
act as a general cell death transducer, such that its FT ligand binding antibody such 
as POM2 could lead to amelioration of disease phenotypes in PMD’s. 
Distinctive subsets of neurons undergo cell death in different PMDs (Saxena and 
Caroni, 2011; Jackson, 2014). Therefore, the protective potential of POM2 against 
ER stress was tested in different types of neurons (see Table 10). Neuronal viability 
was characterized by the cell number with significant neurite outgrowth. In 
interneurons no beneficial effect of POM2 against ER stress could be observed while 
a delay in neurodegeneration was detected in moto- and granule neurons (see Table 
10). The effect of POM2 was less pronounced in motoneurons than in granule 
neurons. The reason for this might be that the motoneurons only express levels of 
PrPC comparable wild type. In addition, they were co-cultured with tga20 astrocytes, 
which also binds POM2 and thus reduce the amount of the antibody available for 
binding to neuronal PrPC. In general, astrocytes have a neuroprotective role (Takuma 
et al., 2004) and may mask the effect of POM2. 
To ensure that the observed effect was PrPC dependent, the experiment was 
repeated in primary granule neurons from PrPC KO mice (see Table 10). In this case, 
POM2 could not counteract the toxicity induced by ER stress. Therefore, the effect 
seems to indeed be PrPC dependent. 
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Table 10: Protective effect of POM2 against ER stress in different types of neurons 
neuron type PrPC level 
POM2 counteracts changes caused by 
ER stress 
comment cell number with 
significant 
outgrowth 
neurite outgrowth 
interneurons wild type no no 
co-culture with tga20 
astrocytes 
motoneurons wild type yes no 
co-culture with tga20 
astrocytes 
cerebellar granule 
neurons 
overexpression yes yes pure neuronal culture 
cerebellar granule 
neurons 
knock out no no pure neuronal culture 
 
Expression levels of specific proteins were analyzed in human neurons pre-incubated 
with POM2 before ER stressor treatment to explore the underlying mechanism of 
POM2 to counteract ER stress-induced neurodegeneration. An overview of the 
results is depicted in Figure 41. 
Interestingly, PrPC levels are significantly upregulated 24h after the induction of ER 
stress with a high dose of TM. This effect was observed in the breast carcinoma 
MCF-7 cell line and in human primary cultures (Dery et al., 2013; Misiewicz et al., 
2013). This supports our hypothesis that PrPC plays a crucial role in the UPR (see 
Figure 41 A). Further studies of this group revealed that the PrPC promotor contains 
an ER stress response element (ERSE) that is regulated by XBP1 (Misiewicz et al., 
2013). Recently it was shown in skeletal muscle cells that activation of Fyn induces 
the Ire1 pathway via mTORC1 (Wang et al., 2015). In Alzheimer’s disease PrPC is 
involved in the activation of Fyn. Assuming that Ire1 signaling in skeletal muscle cells 
and neurons are similar, it could be hypothesized that UPR induces PrP expression 
via the Ire1 pathway, whereby PrP activates Fyn, which leads to a further stimulation 
of Ire1 via mTORC1, thereby creating a positive feedback loop. However, the 
depletion of XBP1 in prion infected mice does not ameliorate the disease phenotype 
(Hetz et al., 2008), which indicates that the signaling interactions must be more 
complex. 
Based on my preliminary data, it seems that POM2 can delay the upregulation of BiP, 
ATF4 and CHOP upon ER stress induction. This suggests that the PERK signaling 
branch of the UPR is affected by POM2 treatment (see Figure 41 B). Therapeutic 
targeting of the PERK pathway has already been applied to prion infected mice. Oral 
treatment with the PERK inhibitor GSK2606414 was able to counteract 
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neuropathological and clinical signs (Moreno et al., 2013). However, the disturbed ER 
homeostasis caused by the drug leads to severe weight loss and mild hyperglycemia 
(Moreno et al., 2013). Therefore, targeting PERK might be not optimal to counteract 
the clinical signs of PMD’s. Additionally, it has already been shown that, depending 
on the type of PMD, inhibition of the PERK pathway can either accelerate or 
attenuate the disease phenotype (Bell et al., 2016; Freeman and Mallucci, 2016).  
Further data are necessary to predict the role of PrP in UPR signaling. However, 
based on the observation that PrPC knock out mice show no severe phenotype apart 
from demyelination (Weissmann and Flechsig, 2003; Steele et al., 2007); it is 
expected that therapeutic targeting of PrPC to counteract PMD’s seems to cause 
fewer side effects. 
Antibody mediated PrPC activation induces caveolin-1 dependent stimulation of 
Fyn/Erk1/2 signaling (Mouillet-Richard et al., 2000; Toni et al., 2006; Pantera et al., 
2009; Shi et al., 2013). It has been reported that the octapeptide region in particular 
is involved in the interaction between PrPC and caveolin-1 (Shi et al., 2013). While 
ER stress leads to an activation of Erk1/2, no significant changes in the expression 
levels of caveolin-1, the phosphorylated forms of Fyn and Erk1/2 could be observed. 
It is known that Erk 1/2 is induced via ER stress but the underlying mechanism 
behind its activation is not yet resolved (Dery et al., 2013; Darling and Cook, 2014). 
Based on my data, it seems that the PrPC/caveolin-1/Fyn interaction is not involved in 
this pathway. 
In summary based on data obtained from the live cell imaging and the translational 
studies, further studies are needed to elucidate the underlying molecular mechanism. 
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No effect upon POM2 treatment 
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Indication that BiP, ATF4 and CHOP 
activation is delayed upon 
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Result 
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clear signaling pattern. 
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Figure 41: Potential Pathways affected by POM2 treatment 
A) Upon ER stress BiP is released form Ire1, which induces auto-phosphorylation of Ire1 that in turn activates unconventional 
splicing of Xbp1 (Hetz, 2012). The transcription factor Xbp1 translocates to the nucleus where it binds to (ERSE)-like elements 
activing the expression of PrP and other genes (Dery et al., 2013; Misiewicz et al., 2013). B) ER stress releases BiP from PERK 
(Hetz, 2012). This leads to the auto-phosphorylation of PERK that stimulates the activation of elF2α, which induces the specific 
expression of ATF4 that translocates to the nucleus where it induces the expression of CHOP among others(Ron and Walter, 
2007). C) PrPC stimulates caveloin-1, which then leads to the phosphorylation of Fyn that via the MAPK pathway activates 
Erk1/2 (Mouillet-Richard et al., 2000; Toni et al., 2006; Pantera et al., 2009; Shi et al., 2013).  
 
According to previous data from our lab (Prof. Magdalini Polymenidou, unpublished), 
intravenous injection of POM2 causes hemolysis in a PrPC dependent manner. This 
effect is most likely caused by antibody mediated complement activation (Walport, 
2001; Dunkelberger and Song, 2010) that leads to lysis of the red blood cells. 
However, to confirm this finding, further studies are necessary, that for example 
assesses levels of complement component 3 (C3), a protein that is specifically 
upregulated after complement activation (Walport, 2001; Carroll, 2004).  
The observation that intravenous injection of POM2 induces hemolysis, excludes 
intravenous administration as a viable method for antibody delivery. Therefore, an 
AAV8 expressing scFv POM2 that lacks the Fc region responsible for complement 
activation (Noris and Remuzzi, 2013; Melis et al., 2015) was generated. Compared to 
injection of the therapeutic antibody, the viral delivery has several advantages. Only 
one administration is necessary to allow continuous expression of the virus secreting 
scFv POM2, while repeated injection of the antibody or Alzet pump would be 
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required, since it is rapidly degraded (Worn and Pluckthun, 2001). This will reduce 
the stress caused in mouse models. In addition, huge amounts of antibody would be 
necessary for intravenous application because only a small proportion of the antibody 
can cross the blood brain barrier (Martins et al., 2016). Therefore, such studies would 
be quite expensive. Another advantage of the virus is the continuous expression of 
the therapeutic agent, in contrast to intravenous application, which causes 
fluctuations in the POM2 blood plasma level and may thereby reduce the efficiency. 
Expression of the virus was tested in brain slices in wild type mice. These studies 
showed that the fluorescent marker labels the infected cells and that scFv POM2 
secretion occurs in amounts sufficient to counteract RML and POM1 mediated 
neurodegeneration in slices. 
To test the protective potential in vivo, AAV8 scFv POM2 was applied to an in vivo 
model of light induced photoreceptor apoptosis in collaboration with Prof. Christian 
Grimm. Transduction of the retina with the AAV8 scFV POM2 did not show any 
protective effect against light induced phototoxicity in the retina. There are several 
explanations for the absence of a therapeutic effect. Based on the design of the virus 
and our data from the slices, the transduced cells should express the fluorescent 
marker tdTomato. In fact, cryosections of the retina do not reveal any red labeling. 
Detection of the scFv POM2 antibody was attempted with an anti-His antibody,  
because a His-Tag is attached to scFv POM2; however, this resulted in only an 
unspecific staining, which is not surprising because scFv POM2 is readily secreted 
and only a small proportion can be found within cells. It is possible that the virus did 
not transduce the retina efficiently or the signal was depleted during the processing 
of the cryosections. In any case, the retinas were further processed for morphological 
analysis. A significant loss of photoreceptors after light exposure in the Balb/c as well 
as Balb/c PrP0/0 mice was observed. However, POM2 was not able to counteract the 
light induced toxicity. In addition, depletion of PrPC did not lead to significant changes 
in photoreceptor loss. 
The light induced photoreceptor damage is caspase-1 dependent (Grimm et al., 
2000). Recent results from our lab suggesting that neuronal loss in prion and POM1 
mediated toxicity is rather Calpain dependent (Sonati et al., 2013; Herrmann et al., 
2015). Based on the different pathways responsible for neurodegeneration, 
participation of PrPC in cell death signaling might change. This would also explain 
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that mild photoreceptor mediated apoptosis could be prevented by overexpression of 
PrPC (Frigg et al., 2006). 
In general, further studies and data are necessary to confirm our hypothesis that 
PrPC could act as a cell death transducer in PMD’s. 
 
6.7. Outlook 
My preliminary data indicate that POM2 may delay ER stress mediated 
neurodegeneration. To elucidate this hypothesis, primary or ESC derived neurons 
could be transduced with a lentivirus expressing a reporter gene like luciferase or 
GFP under the control of regulatory elements that are affected during ER stress. A 
possible target is the ERSE, which is mainly involved in the ATF6 and Ire1 UPR 
signaling branches (Samali et al., 2010). To explore the involvement of the PERK 
signaling branch in more detail, an ATF4 reporter lentivirus that expresses the 
reporter gene under the regulatory elements of ATF4 (ATF4 5′UTR containing the 
uORF1 and uORF2 fused to the ATF4 initiation codon) could be used (Inageda, 
2010). 
The assessment of the therapeutic potential of POM2 in an animal model of 
photoreceptor mediated apoptosis did not reveal a clear result. Therefore, in a next 
step, gene therapy with the AAV8 scFv POM2 should be performed directly in mouse 
models of PMD’s such as prion disease, Alzheimer’s disease, ALS and Huntington’s 
disease. 
Before POM2 gene therapy is applied to animal models, the protective effect of 
POM2 should be tested in in vitro systems of the aforementioned PMD’s. Prion 
organotypic slice culture assay represent a feasible model system (Falsig et al., 
2008; Falsig et al., 2012), for ALS, SOD1 G93A mouse embryonic stem cells 
(mESCs) can effectively model the disease phenotype (Di Giorgio et al., 2007). In the 
case of Alzheimer’s disease, possible models include primary neuronal cultures or 
cell lines treated with neurotoxic amyloid-beta oligomeric peptides (Klein, 2002; 
Benilova et al., 2012) and in Huntington’s disease, one of the established in vitro cell 
model systems (Cisbani and Cicchetti, 2012). 
After the successful application of POM2 to in vitro models of PMD’s, AAV should be 
applied post-symptomatically in the respective mouse model. The potential of scFv 
POM2 to ameliorate the disease phenotype should be characterized according to the 
disease model. For this aim, behavioral studies like Rotarod, foot print analysis, novel 
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object recognition test, survival time and pathophysiological studies could be used 
(see Figure 42). For mouse models where POM2 has a beneficial effect, post-
symptomatic studies should be performed as well. 
 
 
 
*only for ALS and Huntington's disease mice, ** only for Alzheimer’s disease mice 
 
Figure 42: Therapeutic treatment of neurodegenerative mouse models with scFv POM2 
Mouse models of several neurodegenerative diseases like prion disease, ALS, Alzheimer’s and Huntington’s should undergo 
gene therapy with scFv POM2. To evaluate the potential of POM2 to ameliorate the disease phenotype, behavioral studies like 
Rotarod, footprint analysis, novel object recognition test or survival and pathophysiological studies should be assessed.  
(image Rotarod and Footprint: (Brooks and Dunnett, 2009)) 
 
Currently there is no cure for the selected PMD’s. Involvement of PrPC in the 
pathology of these diseases would represent a pioneering discovery in this field and 
reveal the potential of PrPC as a new therapeutic target for neurodegenerative 
diseases. 
 
6.8. Material and Methods 
All reagents are purchased at Thermo Fischer if nothing else is stated. 
 
6.8.1. Mice 
The housing of mice and animal experiments were performed according to Swiss 
Animal Protection Law and in compliance with the regulations of the veterinary office 
(canton Zurich). For our studies the following mice were included PrnpZH1/ZH1 mice 
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(Bueler et al., 1992), PrnpZH3/ZH3 mice (Nuvolone et al., 2016), C57BL/6-tga20 mice 
(McHugh et al., 2012), B57BL/6J (The Jackson laboratory), Balb/c (Harlan 
laboratories), Prnp0/0 Balb/c (Frigg et al., 2006). 
 
6.8.2. Primary cell culture 
6.8.2.1. Cerebellar granule neurons 
To generate cerebellar granule neurons, a modified protocol from the Manzini group 
was used (Lee et al., 2009). In detail, 4 to 6 days old pups were decapitated and put 
in dissection buffer (6.7ml Glutamax 45%, 5ml P/S, 50 ml HBSS ad up to 500 ml with 
sterile water). The head was fixed with forceps and the brain was accessed by 
inserting micro dissecting scissors into the foramen magnum and cutting straight 
toward the eyes. With the help of forceps the skin was removed and the skull was 
lifted up to expose the brain. After pinching off the cerebellum and surrounding 
midbrain, the tissue was transferred into a new plate with dissection buffer. The 
cerebellum was separated from the midbrain, brain stem and choroid plexus. After 
gentle removal, the meninges were peeled off and the cerebellum was transferred 
into a plate with fresh dissection buffer. For digestion of the tissue the dissection 
buffer was removed and 1 ml papain (Worthington) and 125 ul DNase (Worthington) 
(for 1-3 cerebelli) were added and incubated for 15 min at 37°C. Next the cells were 
triturated and passed to a 70 um cell strainer to remove cellular debris. To separate 
the viable from death cells, the cell suspension was loaded onto 5ml Ovomucoid 
inhibitor (Worthington) and a gradient centrifugation at 500 rcf for 5 min was 
performed. After removal of the supernatant the remaining viable cells were dissolved 
in cerebellar granule neuron media (Neurobasal media containing 1x GlutaMAX, 1x 
P/S, 1x B27 supplement and 250 uM KCl) and plated on Lamin/Poly-D-Lysine coated 
plates. 
 
6.8.2.2. Primary astrocytes culture 
5.8.2.3 
 
6.8.3. Plating embryonic stem cells (ESCs) 
Irradiated mouse embryonic fibroblasts (MEF) feeder cells (amsbio, GSC-6001G) 
were seeded on plates pre-coated with gelatin (Millipore, #ES-006-B) in MEF-media 
(DMEM, 50 % fetal bovine serum (FBS), 1% penicillin/streptomycin, 1 % Glutamax, 
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1 % Non-essential amino acids (NEAA)). mESCs were cultured on this plates in 
mESC-media (Knockout D-MEM, 90 ml ES Cell FBS, 6 ml beta-mercaptoethanol, 6 
ml NEAA, 1 % penicillin/streptomycin, 1 % Glutmax, 1’000-2’000 units/ml leukemia 
inhibitory factor (Lif)).  
 
6.8.4. Preparation of astrocytes for sorting mESCs 
See 5.8.5 
 
6.8.5. Derivation of neurons from mESCs 
See 5.8.6 
 
6.8.6. FACS-sorting 
5.8.7 
 
6.8.7. Derivation of neurons from iPSC derived neurons 
5.8.8 
 
6.8.8. Estimation of serum hemoglobin using o-toluidine 
For estimation of the hemoglobin concentration, the Goyal and Basak protocol was 
used (Goyal and Basak, 2009). In brief 100 ul of o-Toluidine solution (0.4 g o-
toluidine dissolved in 20 ml glacial acetic acid and 80 ml Ethanol) were mixed with 
100 ul hydrogen peroxide solution (6.67 ml hydrogen peroxide (30 % (v/v)) add up to 
100 ml with analytical water and add 2.26 gm sodium acetate). After an incubation 
time of 5 min 1 ul of the hemoglobin solution were added, mixed and followed by a 
subsequent kinetic measurement at 630 nm for 180 sec. The rate of the kinetic 
reaction is directly proportional to the hemoglobin concentration (Goyal and Basak, 
2009) 
 
6.8.9. Organotypic slices 
Organotypic cerebellar slices were prepared according to a modified protocol from 
Falsig et al. (Falsig et al., 2008; Falsig et al., 2012). In brief, 300 μm thick sections of 
cerebella from 13 day old pups were cut with the vibratome and kept in Gey’s 
balanced salt solution (GBSS) (NaCl 8 g l–1, KCl 0.37 g l–1, Na2HPO4 0.12 g l–1, 
CaCl2 2H2O 0.22 g l–1, KH2PO4 0.09 g l–1, MgSO4 7H2O 0.07g l–1, MgCl2 6H2O 
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0.210 g l–1, NaHCO3 0.227 g l–1) supplemented with the glutamate receptor 
antagonist kynurenic acid (1 mM) at 4°C. For roller tube cultures the slices were 
embedded in a plasma clot on a coverslip pre-coated with Poly-D-Lysine (ref). 2 
slices were plated per coverslip. 
 
6.8.10. Transduction organotypic slices 
For viral infection, brain slices were incubated in 500 ul slice-culture medium” (50% 
vol/vol MEM, 25% vol/vol basal medium Eagle and 25% vol/vol horse serum 
supplemented with 0.65% glucose (w/vol), penicillin/streptomycin and glutamax 
(Invitrogen)) containing a defined amount of AAV (titer 108-1011). The slices were 
kept at 1h at 4°C before they were put into a specific incubator that contains a 
rotating wheel for the tubes. After 2 days 250 ul additional slice-culture media were 
and complete media was exchange every week. 
 
6.8.11. Morphological analysis  
5.8.11 
 
6.8.12. Western Blot 
See 5.8.12 
Antibodies used: ATF4 (CST, # 11815), BiP (CST, #3183), Caveloin-1 (CST, #3238), 
CHOP (CST, #5554), P-Erk1/2 (CST, #4370), P-Fyn (abcam, # ab182661), POM1 
(Polymenidou et al., 2008),  
The following blocking buffers were used: 
 5 % w/v Albumin IgG free, 1 x TBS (20 mM Tris-Base, 150 mM NaCl),  
pH =7,4, 0.1 % Tween-20 (ATF4, BiP, CHOP, P-Erk1/2), 
 5 % w/v milk, 1 x PBS, 0.1 % Tween (POM1, Caveloin-1) 
 5 % w/v TopBlock, 1 x PBS, 0.1 % Tween (P-Fyn) 
 
 
6.8.13. ELISA for determination of scFv POM2 in the media supernatant 
A 96 well tissue culture plate was coated with 50 ul/well of rPrP (3 ug/ml) in 50 mM 
Tris. After incubation overnight at 4°C, the plate was washed 5 times with washing 
buffer (PBS, 01.% Tween) and 100 ul/well of blocking buffer (5% w/v TopBlock, 0.1% 
Tween-20) was added and incubated for 2h at room temperature. After removal of 
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the blocking buffer the samples were added and incubated for 2h at room 
temperature. The plate was washed 6 times with washing buffer before 50 ul/well 
Anti-6X His tag® antibody (Biotin) (ab27025) (1:1’500) in sample buffer (= slice 
culture media) was added. This step was followed by 6 times washing with washing 
buffer 50 ul/well of streptavidin-HRP (#554066, Becton Dickinson AG) 1:1000 in 
sample buffer was added and incubated for 1h at room temperature. After 6 times 
washing with washing buffer 50 ul/well chromogen (BIOSOURCE 16A8/1) was added 
and incubated up to 30 min. 50 ul/well stop solution (H2SO4 0.5 M) was added and 
plate were measured at 450 nm. 
 
6.8.14. Phototoxicity 
Viral infection of the mouse eye and the light induced phototoxicity experiment was 
performed by the group of Prof. Christian Grimm. Before the study started the mice 
were kept in a 12 h:12 h light/dark cycle. The mouse eye was infected with the AAV8 
expressing scFv POM2 via intravitreal injection of the virus. 1 µl AAV8 expressing 
scFv POM2 was injected in the left eye and 1 µl PBS was injected in the right eye of 
one mouse. The mice were then kept for 2 weeks to ensure stable expression of the 
virus. After dark adaptation overnight, the pupils were dilated and the mice were 
exposed to 10’000 lux for 2h. After light exposure, the mice were immediately 
returned to the 12 h:12 h light/dark cycle and sacrificed after 10 days. 
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